University of Montana

ScholarWorks at University of Montana
Graduate Student Theses, Dissertations, &
Professional Papers

Graduate School

2009

Consequences of Aryl hydrocarbon receptor activation in dendritic
cells
Jaishree Bankoti
The University of Montana

Follow this and additional works at: https://scholarworks.umt.edu/etd

Let us know how access to this document benefits you.
Recommended Citation
Bankoti, Jaishree, "Consequences of Aryl hydrocarbon receptor activation in dendritic cells" (2009).
Graduate Student Theses, Dissertations, & Professional Papers. 235.
https://scholarworks.umt.edu/etd/235

This Dissertation is brought to you for free and open access by the Graduate School at ScholarWorks at University of
Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an
authorized administrator of ScholarWorks at University of Montana. For more information, please contact
scholarworks@mso.umt.edu.

CONSEQUENCES OF ARYL HYDROCARBON RECEPTOR ACTIVATION IN
DENDRITIC CELLS
By
Jaishree Bankoti
Bachelor of Sciences in Zoology, Gargi College, University of Delhi, Delhi, India
Master of Sciences in Biosciences, Jamia Millia Islamia, Delhi, India
Dissertation
Presented in partial fulfillment of the requirements
for the degree of
Doctor of Philosophy
in Toxicology
The University of Montana
Missoula, MT
Fall 2009
Approved by:
Perry Brown, Associate Provost for Graduate Education
Graduate School
Dr. David M. Shepherd, Chair
Department of Biomedical and Pharmaceutical Sciences
Dr. Kevan Roberts
Department of Biomedical and Pharmaceutical Sciences
Dr. Howard Beall
Department of Biomedical and Pharmaceutical Sciences.
Dr. Keith Parker
Department of Biomedical and Pharmaceutical Sciences
Dr. Scott Wetzel
Division of Biological Sciences
Dr. Paige Lawrence
Department of Environmental Medicine, School of Medicine and Dentistry,
University of Rochester, Rochester, NY (External Committee Member)

Bankoti, Jaishree., Fall 2009

Toxicology

CONSEQUENCES OF ARYL HYDROCARBON RECEPTOR ACTIVATION IN
DENDRITIC CELLS
Chairperson: Dr. David M. Shepherd
Abstract
TCDD (dioxin) causes immunosuppression via activation of the Aryl hydrocarbon
receptor (AhR). Dendritic cells (DCs), the professional antigen-presenting cells in
the immune system, are adversely affected by TCDD. However, limited
information exists regarding the effects of AhR activation on DCs. We evaluated
the consequences of AhR activation by TCDD on both steady-state and
inflammatory DCs using in vivo and in vitro approaches, respectively. We
hypothesized that AhR activation alters DC homeostasis and differentiation
leading to generation of immunosuppression. C57Bl/6 mice gavaged with an
immunosuppressive dose of TCDD (15 µg/kg) displayed decreased frequency
and number of splenic CD11chigh DCs on day 7. Moreover, TCDD induced a
selective loss of the CD11chighCD8α-33D1+ splenic DCs subset, specialized at
activating CD4+ T cells, but not the regulatory CD11chighCD8α+DEC205+ splenic
DCs. Additionally, TCDD increased the expression of CD86 and CD54, while
decreasing the frequency of CD11a and MHC II on the splenic CD11chigh DCs.
Although TCDD did not alter the number and frequency of CD11clow splenic DCs,
it decreased their MHC II and CD11a expression. The loss of CD11chigh DC was
independent of an apoptotic event but involved a CCR7-mediated migratory
event. Popliteal and brachial lymph node (PBLNs) CD11c+ cells displayed
elevated levels of MHC II and CD40, but not DC loss following TCDD exposure.
To examine the effects of TCDD on inflammatory DCs, BMDCs were generated
in the presence of GM-CSF and vehicle or TCDD. TCDD decreased CD11c
expression but increased MHC II, CD86 and CD25 expression on these BMDCs.
These effects were AhR-dependent but not exclusively DRE-mediated.
Additionally, TCDD modulated antigen uptake and increased LPS- and CpGinduced IL-6 and TNF-α levels but decreased nitric oxide production by the
BMDCs. TCDD downregulated LPS- and CpG-induced p65 levels and induced a
trend towards upregulation of RelB levels in BMDCs. Despite the induction of
suppressive mediators IDO1, IDO2 and TGFβ3, TCDD-BMDCs failed to
suppress T cell activation in vivo or induce the generation of adaptive T-regs in
vitro. Collectively, our data suggest that AhR activation disrupts DC homeostasis,
modulates DC differentiation, TLR responsiveness and induces a regulatory
phenotype, effects that may underlie TCDD-induced immunosuppression.
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CHAPTER 1
INTRODUCTION
This study describes the effect of Aryl hydrocarbon receptor (AhR)
activation on the fate and function of dendritic cells (DCs). The introductory
chapter will: 1) broadly describe the immune system with a central focus on DCs
and T cells 2) provide detailed information on 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) and the AhR, and lastly 3) describe TCDD immunotoxicity.
The Immune system
Following entry of a pathogenic organism in our body, the immune system
is activated to limit the pathogenic insult to the host. The immune system
achieves this function in a series of coordinated steps carried out by two
specialized branches referred to as the innate and the adaptive immune system.
Although the central purpose of both is to protect the host, the innate and the
adaptive immune system differ in their mode of action as described below.
Innate Immune System: The innate immune system constitutes the first line of
defense against pathogenic insult and encompasses anatomical, physiological,
phagocytic, and inflammatory barriers. The anatomical barrier consists of skin,
epithelial layers and mucous membranes, which form an immediate physical
barrier to most infectious agents preventing their direct entry into the body. The
physiological barrier includes fatty acids, enzymes such as lysozyme, and
antibacterial peptides that further prevent pathogen establishment. Additionally,
the normal flora of the body secretes factors that are detrimental to pathogens
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and prevent colonization. Pathogens that escape these initial barriers, encounter
specialized cells of the innate immune system, which consists of neutrophils,
macrophages, natural killer cells, eosinophils and dendritic cells (DCs). These
may phagocytose the pathogen thereby killing it intracellularly. Alternately,
certain innate immune cells may also process and present portions of the
pathogen to adaptive immune cells such as T cells and B cells. In this capacity,
macrophages and DCs are referred as antigen presenting cells (APCs). These
cells express cell surface proteins as well as secrete soluble inflammatory
mediators that serve to attract and stimulate the adaptive immune cells at the site
of injury as well as the draining lymph nodes.
Antigen presenting cells: Antigen presenting cells function to detect pathogen
in the periphery, process and present it to the lymphocytes in the draining lymph
nodes and subsequently activate the adaptive immune system. In addition to the
ubiquitously expressed major histocompatibiliy antigen I (MHC I), APCs express
MHC II and B7 molecules also known as CD80 (B7-1) and CD86 (B7-2) (Bryant
and Ploegh, 2004). Effective activation of T cell by an APC is described using the
three-signal hypothesis. As shown in Figure 1-1, three signals are necessary for
complete activation of T cell by APCs. Signal one comprises delivery of the MHC
bound antigen to the T cell receptor (TCR). Signal two constitutes the binding of
B7 co-stimulatory signals to cognate CD28 receptors on T cells. Secretion of
soluble mediators, such as cytokines from activated APCs constitutes signal
three. The nature of the secreted cytokine in turn governs T cell polarization as
discussed later in this chapter (Goldsby, 2003). Appropriate and timely delivery
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Figure 1-1

Figure 1-1. Effective activation of a T cell by an APC is dependent on three
signals. Signal 1 is the interaction of MHC bound Ag with the T cell receptor.
Binding of costimulatory molecules expressed on DC with cognate molecules on
the T cells generates signal 2. APCs also secrete cytokines that contribute to T
cell polarization, and this interaction constitutes signal 3.The lack of these signals
leads to T cell anergy, depletion or tolerance. Adapted from Cools et al., 2007.
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of the three signals is required for a sucessful T cell response. A lack of these
signals can lead to anergy, deletion or tolerance. Anergy refers to a state in
which a T cell is inactivated and hyporesponsive. For instance, delivery of signal
1 in the absence of costimulation can lead to T cell anergy. Additionally,
maturational state of an APC also influences the development of a T cell
response as discussed in the following section.
Dendritic cells: Amongst the existing varieties of APCs, DCs are considered the
most potent APCs that execute both innate and adaptive functions.

DCs

constitute part of the first line of defense against invading pathogens and play a
critical role in the generation of effective innate immunity to pathogenic
challenge. Crucial functions of DCs include their ability to take up antigens,
secrete cytokines, and recognize unique pathogen associated molecular patterns
(PAMPs) via pattern recognition receptors (PRRs). The PRRs such as the toll
like receptors (TLRs) encompasses membrane-bound receptors such as TLR4,
and intracellular receptors such as TLR9.

As shown in Figure 1-2, TLR4

recognizes lipopolysaacharide (LPS), whereas TLR9 specifically recognizes
cytosine phosphate guanine (CpG) motif. TLR stimulation activates DCs leading
to the secretion of proinflammatory cytokines such as TNF-α and IL-6, which
further modulate the developing immune response by orchestrating T cell
polarization.
In addition, DCs also regulate adaptive immunity and are considered to be
the most potent for initiating activation of naïve T cells. Concomitant with the
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constitutively high expression of MHC II, DCs also express T cell costimulatory
molecules such as CD80 and CD86 (Greenwald et al., 2005). Following
encounter with pathogen or host-derived inflammatory products such as
cytokines, immature DCs are induced to mature. This maturation is associated
with upregulation of chemokine receptors such as CCR7 resulting in migration to
the lymph nodes, where subsequent interactions with T cells lead to generation
of adaptive immunity (Sanchez-Sanchez et al., 2006). As shown in Figure 1-1,
activation of a T cell by a DC requires three signals. In the most traditional form
of antigen (Ag) presentation, DCs uptake antigen and present short, Ag-derived
peptides, bound to MHC to the T cell. Intracellulary-derived Ag such as viral
products are usually presented via MHC I molecules to the TCR of CD8+ T cells,
and exogenously-derived antigen such as bacterial products are presented via
MHC II to the TCR of CD4+ T cells (Cresswell, 2005). Following receptor
engagement, costimulatory molecules on DCs such as CD80 and CD86 bind and
activate surface receptors expressed on T cells such as CD28 (Lenschow et al.,
1996). Other accessory molecules such as CD54:CD11a and CD40:CD154 also
play important roles in T cell activation

(Croft and Dubey, 1997).

Final

differentiation of a T cell into an effector cell is mediated by cytokines secreted by
the DCs and other immune and non-immune cells. Therefore, full T cell activation
and generation of an immunogenic response is dependent on appropriate and
timely presentation of three distinct signals.
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Figure 1-2

Figure 1-2. TLRs and their ligands: Dendritic cells express both surface bound
and intracellular TLRs. Binding of ligands to their respective TLR activates a
signaling cascade leading to induction of downstream transcription factors and
drives the activation and maturation of DCs.
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An accumulating body of evidence suggests that DCs also function to
generate and maintain Ag-specific unresponsiveness in central and peripheral
immune tissues (Steinman et al., 2003). Such DCs are referred to as tolerogenic
or regulatory DCs (DCregs). There are multiple ways in which DCs can induce T
cell tolerance. For instance, T cells are tolerized when their TCR engages
peptide-MHC complexes on an immature DC (Forster and Lieberam, 1996; Kurts
et al., 1996). Alternately, numerous studies have shown that Ag presentation in
the absence of co-stimulation leads to T cell anergy (Adler et al., 1998; Schwartz,
2003; Cools et al., 2007). Similarly, DCs expressing low levels of MHC Class II
and costimulatory molecules are also inefficient at inducing T cell activation (Lutz
et al., 2000). Recently, DCregs have been characterized by the expression of
maturation markers and the immune-inhibitory enzyme indoleamine 2,3
dioxygenase (IDO) (Mellor and Munn, 2004; Popov and Schultze, 2008). IDO
enzymatically degrades the essential amino acid tryptophan generating
metabolites known as kynurenines which block T-cell proliferation resulting in T
cell apoptosis (Grohmann et al., 2003). In addtion to expression of IDO,
interaction of CD86 on a DC with CTLA4 expressed on T cell is also shown
suppress T cell responses.
DCs are a heterogeneous immune cell population (Vremec et al., 2000;
Shortman and Liu, 2002). Initial attempts to classify DCs focused on the idea that
there were two distinct DC lineages: myeloid DCs and lymphoid DCs. It has
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become increasingly evident, however, that multiple DCs subsets exist beyond
this. Currently, DCs are classified into three distinct cell types: pre DCs,
conventional DCs and inflammatory DCs (Table 1-1) (Shortman and Naik, 2007).
Pre DCs such as plasmacytoid DCs (pDCs) and monocytes develop into DCs
following an inflammatory or microbial stimulus (Shortman and Naik, 2007).
Conventional DCs can be further categorized into migratory DCs and lymphoidtissue-resident DCs. Lymphoid-resident DCs as the name suggests, reside in the
lymphoid tissue and exhibit no migratory capacity. In the spleen, these DCs are
further classified into 2 subtypes based on the presence of the marker CD8α,
and are referred to as CD8α+DEC205-and CD8α-33D1+. The aforementioned
splenic DC subsets differ in their anatomic location and functional properties.
CD8α+DEC205+ DCs reside in the T cell zone and specialize in the uptake of
dying cells (Dudziak et al., 2007). More recently, a Treg-inducing function has
been ascribed to these DCs (Yamazaki et al., 2008). In contrast, CD8α-33D1+
DCs found in the marginal zone specialize in CD4+ T cell activation (Dudziak et
al., 2007). In addition, inflammatory DCs constitute a novel DC population that
are absent in the steady-state and only appear following an inflammatory insult.
These DCs, characterized by copious production of TNF-α and inducible NO
synthase (iNOS), are derived in vitro using GM-CSF/IL4 (Xu et al., 2007).
Even with such heterogeneity, DCs constitute a very limited pool of the total
immune cell population and the number of DCs obtainable from an animal is
extremely limited. Thus, various strategies using bone marrow precursors have
emerged to generate large number of DCs in culture. DC populations may be
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Table 1-1: Different types of dendritic cells. Adapted from (Shortman and Naik,
2007)

Types of dendritic cells
Pre-dendritic cells
Exhibit capacity to develop into DCs
Examples: pDCs, monocytes
Conventional dendritic cells
Migratory dendritic cells
Migrate to the lymphoid areas following Ag capture from the periphery
Examples: Langerhan cells, dermal DCs
Lymphoid-tissue resident dendritic cells
Do not migrate to the lymphoid organ
Spend their life span in one lymphoid organ
Examples: CD4+CD8-cDCs, CD4-CD8- cDCs and CD4-CD8+ cDCs.
Inflammatory dendritic cells
Absent in the steady-state
Appear following inflammatory insult
Examples: Tip DCs
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generated in vitro using the growth factors Granulocyte Macrophage Colony
stimulating factor (GM-CSF) and FMS-like tyrosine kinase 3 ligand (Flt3-L). GMCSF is widely used for development and expansion of inflammatory DCs in vitro.
These inflammatory DCs in vitro are characterized by production of TNF-α and
inducible nitric-oxide-synthase (Tip DCs)(Xu et al., 2007). Flt3-L, on the other
hand, generates steady-state pDCs and cDCs. Additionally, studies from several
labs have demonstrated that a single injection of the hematopoietic cytokine,
Flt3-L enhanced the production of both myeloid and lymphoid DCs that
encompass both pDCs and cDCs (Maraskovsky et al., 1996; Pulendran et al.,
1999; Brawand et al., 2002; Gilliet et al., 2002). The importance of this cytokine
in promoting the development of DCs was demonstrated by studies
demonstrating that Flt3 L KO mice displayed reduced number of pDCs, cDCs
and NK cells.
In addition to the aforementioned growth factors, DC development is
dependent on the nuclear transcription factor NF-kB, which mediates the
expression of numerous genes involved in cellular processes such as apoptosis,
proliferation and inflammation. The mammalian NF-kB transcription family is
composed of five distinct members: p50, p52, p65 (RelA), c Rel and Relb
(Moynagh, 2005; Hoffmann et al., 2006). In unstimulated DCs, NF-kB members
reside in the cytosol in an inactive form via interactions with inhibitory IkB
proteins. NF-kB signaling ensues in two distinct pathways referred to as the
canonical signaling pathway and the non-canonical signaling pathway (Figure 1-
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3). The canonical signaling involves activation of the heterodimeric p65-p50
Figure 1-3

A.

B.

Figure 1-3. Overview of canonical and non-canonical NF-kB signaling
pathways A) The canonical NF-kB signaling pathway involves binding of a
ligand to a receptor leading to activation of IKK complex. The IKK complex
degrades IkB leading to translocation of active NF-kB components Rel A and p50
into the nucleus, where they initiate transcription of genes. B) The non-canonical
pathway involves binding of a ligand to a receptor, ultimately leading to activation
of the IKK complex. The IKK complex functions to release the active NF-kB
components RelB/p52 into the nucleus, where they initiate transcription of genes
regulated by kB sites. Figure adapted from www.abcam.com.
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complex and is initiated following binding of a ligand to a cell surface receptor
such as TLRs.

This leads to recruitment of adaptors such as TRAF to the

cytoplasmic domain of the receptor followed by recruitment of the IKK complex
that phosphorylate and degrades the IkB inhibitor, thus releasing the active NFkB members (p65-p50). This heterodimeric complex then translocates into the
nucleus and activates transcription of target genes. The non-canonical signaling
on the other hand involves activation of p100-RelB complex following
phosphorylation of p100 through IKK. Although distinct, crosstalk between the
Canonical and non-canonical NF-kB signaling pathway has been shown to
regulate inflammatory and developmental signaling (Basak and Hoffmann, 2008).
Adaptive Immune System: The non-specific nature of the innate immune
system is often inadequate for the complete clearance of pathogens. In these
instances, specificity by the immune system is conferred by the adaptive immune
system as discussed below. The adaptive immune system includes effector cells
including B and T lymphocytes, which recognize and respond to pathogenic
insult in an an Ag-specific manner. The Ag-specific nature of the adaptive
immune system imparts specificity to the immune system and also generates
immunological memory (Charles A. Janeway, 2005).
T cells: T cells are hematopoietically-derived cells which originate in the bone
marrow and reach full maturation in the thymus, where the process of positive
and negative selection directs their development into two functional types: CD4+
and CD8+ T cells. The T cells express the T cell receptor (TCR) that recognises
and responds to processed antigenic peptides. Full activation of a T cell requires
12

the delivery of three signals by an APC as described previously in Figure 1-1.
CD4+ T cells commonly referred to as T helper cells (Th) aid the orchestration of
adaptive immune responses by contributing to the activation of B cells and CD8+
T cells and the generation of humoral and cell-mediated immune responses,
respectively. Initial studies divided a mature CD4+ T cells into two distinct cell
types referred to as Th1 and Th2 based on their cytokine profile and effector
functions (Mosmann et al., 1986). Th1 cells provide immunity to a variety of
intracellular pathogens and produce cytokines such as IFN-γ, lymphotoxin-α (LTα) and IL-2 (Mosmann and Coffman, 1989a; Mosmann and Coffman, 1989b; Zhu
and Paul, 2008). Th1 cells express the transcription factor T-bet and require IFNγ and IL-12 for their differentiation (Szabo et al., 2000; Zhu and Paul, 2008). In
contrast, Th2 cells participate in host defense against extracellular parasites and
produce cytokines IL-4, IL-5, IL-10, IL-9 and IL-13 (Mosmann and Coffman,
1989b; Paul and Seder, 1994; Zhu and Paul, 2008). Th1 cells express the
transcription factor GATA-3 and require IL-4 and IL-2 for differentiation (Kurata et
al., 1999; Zhu et al., 2001). Extensive studies in the past decade have identified
2 novel Th subsets, in addition to these classic Th cell subtypes referred to as
the Tregs and Th17 cells
Two distinct types of regulatory T cell have been described: natural T
regs that arise in the thymus and inducible/adaptive Tregs, that form from
CD4+CD25-Foxp3- precursors in the periphery (Shevach, 2006; Sakaguchi et al.,
2008; Yamazaki and Steinman, 2009). Regulatory T cells (T-regs), characterized
by CD25 and Foxp3 expression as well as IL-10 and TGF β, play a critical role in

13

maintenance of self-tolerance, as well as inflammatory responses.
The most recent addition to the Th family is the Th17 subset, characterized
by expression of the transcription factor RORγT and secretion of the cytokine IL17 (IL-17a, IL-17f) and IL-22 (Yao et al., 1995; Ivanov et al., 2006). Th17 cells
function in the clearance of extracellular bacteria and have been implicated in the
generation of autoimmunity (Weaver et al., 2006; Zhu and Paul, 2008).
Lastly CD8+ T cells, also referred to as cytotoxic T lymphocytes (CTLs),
recognize an antigen in an MHC I-restricted manner. Their prime effector function
is to detect and kill virally-infected cells, tumor cells and allogenic cells that differ
in MHC Class I expression. Following its activation, CD8+ T cells employ a series
of effector mechanisms to achieve immunity. These range from inducing extrinsic
apoptotic pathways to secretion of perforin and granzymes (Charles A. Janeway,
2005).
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is a member of the family of
chemicals referred to as halogenated aromatic hydrocarbons (HAHs) (Figure 14). Other members of this family include structurally-related chemicals such as
dibenzofurans (PCDFs), biphenyl (PCBs) and napthlenes. Amongst these
chemicals, TCDD is most potent at inducing toxicity and is considered as the
prototypical HAHs. TCDD is generated and released into the environment as a
by-product of various industrial activities such as waste incineration, metal
smelting and burning of chlorine-containing organic chemicals such as plastics
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Figure 1-4
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Figure 1-4. Chemical structures of various halogenated aromatic hydrocarbons
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(Birnbaum, 1994). Additionally, unintentional releases of TCDD into the
environment have also occurred in the past. For instance, in Seveso an
explosion released around 300-1200 kg of TCDD into the environment (Dickson
and Buzik, 1993). TCDD has a molecular weight of 322 and occurs as white
crystalline solid. A relatively stable compound, TCDD is resistant to breakdown
by acids, hydrolysis and heat (Webseter and Commoner 1994). However, TCDD
degrades slowly via photodegradation. As TCDD and related HAHs are lipophilic
in nature, they exhibit a propensity to accumulate in fatty tissues and concentrate
up the food chain from plants to human (Schecter et al., 1994a; Schecter et al.,
1994b). The half-life of TCDD ranges from 7 to over 10 years in humans
(Aylward et al., 2005). Human exposure to TCDD results from diet, inhalation and
skin contact. Of these, dietary intake constitutes by far the most important route
of exposure and accounts for greater than 90% of dioxin exposure via fatty foods
such as fish and dairy products (Brouwer et al., 1998).
Aryl hydrocarbon receptor
The Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription
factor belonging to the basic-helix-loop–helix (bHLH) family that mediates the
toxic manifestations of TCDD and dioxin-like chemicals (Schmidt and Bradfield,
1996). AhR activation by TCDD has been implicated in the initiation of variety of
biochemical and toxic responses such as chloracne, developmental and
reproductive toxicity, carcinogenesis and immune suppression (Bock, 1994).
Cloning of the AhR revealed important information regarding its structure and
function (Whitlock, 1993). In the cytosol, the receptor exists as part of a protein
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complex with 2 heat shock proteins (hsp90) and XAP 2 (Carver et al., 1994;
Meyer et al., 1998). In the classical schematic of AhR signaling depicted in
Figure 1-5, binding of the ligand to the cytosolic receptor induces a
conformational change leading to dissociation of hsp90 and XAP2 from the
receptor. This is followed by association of the ligand-bound receptor with the
helix-loop-helix type nuclear transcription factor, AhR nuclear translocator (Arnt)
(Reyes et al., 1992). Next, the AhR-ARNT heterodimer binds specific sequences
termed dioxin responsive elements (DREs) in DNA leading to activation of AhR
The core consensus sequence within the DRE has been identified as 5’GCGTG3’. In addition to Cyp1A1, which harbors nine DREs in its 5’ promoter region,
other genes involved in growth, differentiation and homeostasis such as c-fos
and c-jun (Hankinson, 1995; Safe et al., 1998; Nebert et al., 2000). Binding of the
AhR-ARNT heterodimer to DREs also activates transcription of the Aryl
hydrocarbon receptor repressor (AhRR), which competes with AhR for formation
of the heterodimeric complex with Arnt and binding to DREs in target genes. The
AhRR initiates a feedback mechanism regulating the activity of the AhR (Mimura
et al., 1999; Watanabe et al., 2001; Karchner et al., 2002). In addition, AhR is
regulated by protein degradation by ubiquitination mediated by the 26 S
proteosome (Ma and Baldwin, 2000; Ma et al., 2000).
Non-DRE mediated AhR signaling: Although binding of activated AhR to DREs
mediates TCDD toxicity in many physiological systems, an accumulating body of
evidence shows that activated AhR interacts with other signaling pathways
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Figure 1-5

Figure 1-5. The classical AhR signaling is shown. (1) The prototypical AhR
ligand TCDD enters into the cell via passive diffusion and binds the AhR with
high affinity (2) Ligand binding causes dissociation of hsp90 and XAP2 from the
receptor. (3) Ligand-bound AhR translocates into the nucleus and interacts with
the AhR nuclear translocator (ARNT). (4) The heterodimeric AhR-ARNT complex
binds specific DNA sequences known as Dioxin response elements (DREs),
leading to altered gene transcription of target genes (5) Toxicities are manifested
in several physiological systems due to AhR activation regulated gene battery
(Schmidt and Bradfield, 1996; Whitlock, 1999).
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resulting in cell cycle arrest, inhibition of cellular proliferation, anti-estrogenic
effects, and modulation of inflammatory responses. Non-DRE mediated AhR
signaling pathways include interactions between the AhR and retinoblastoma
protein (Rb), E2F1, Estrogen receptor (ER), MAP kinases and NF-kB members.
Two distinct models have been proposed to describe the inhibitory effect
of TCDD on cellular proliferation (Marlowe and Puga, 2005; Puga et al., 2009).
One model involves AhR-Rb interactions and the other supports the AhRmediated induction of cyclin-dependent kinase inhibitors (CDKs) (Puga et al.,
2009). The AhR associates with hypophosphorylated Rb and prevents its
phosphorylayion in the G1 stage, which represses the E2F-dependent gene
expression, thus inhibiting progression through the cell cycle (Ge and Elferink,
1998; Puga et al., 2000). (Puga et al., 2000; Puga et al., 2009). An alternate
explaination for the induction of G1 arrest by TCDD is the induction of cyclin
dependent kinase inhibitors such as p27kip. Huang and Elferlink demonstrated in
TCDD-induced AhR-mediated G1 arrest to be partially regulated by direct AhR
transcriptional activity in rat hepatoma cells. The same study also provided
evidence that AhR-mediated G1 arrest required the Arnt protein (Huang and
Elferink, 2005).
Another non-DRE event implicated in mediating TCDD toxicity is the
activation of c-src. Binding of the AhR ligand to the receptor liberates the AhR
from the Hsp complex leading to activation of c-src. The c-src then activates cras proteins and the MAP kinases pathway, ultimately activating nuclear
transcription factors such as AP1.

In this context, TCDD induces p38 and
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ERK1/2 activation in an AhR-independent manner resulting in enhanced TNF-α
production (Park et al., 2005).
Similar to the AhR, the Estrogen receptor (ER) is a ligand-activated
transcription factor and several studies have demonstrated AhR-ER crosstalk.
Activated AhR exerts antiestrogenic effect by inhibiting ER activity. For instance,
TCDD represses the induction of ER target genes such as pS2, cathepsin D, cfos and cyclin D1 (Beischlag et al., 2008). Several hypothesis emerged to explain
the repression of these ER target genes. The first explanation proposed
enhanced E2 metabolism mediated by TCDD-induced expression of Cyp1A1 and
Cyp1B1 (Spink et al., 1990; Spink et al., 1992). An alternate mechanism
proposed TCDD-mediated activation of proteosomes leading to increased ER
degradation (Wormke et al., 2003). Studies have also shown activated AhR to
redirect ER from ER target genes to AhR target genes, suggesting that AhR
regulates ERα protein levels and subsequently influence the estrogenic response
(Matthews et al., 2005). Additionally, recent studies have described the AhR to
function as a ligand-dependent ubiquitin ligase promoting the degradation of ERα
and modulating steroid receptor function (Ohtake et al., 2009).
Recently, evidence has emerged implicating crosstalk between the AhR
and NF-kB (Ruby et al., 2002; Vogel and Matsumura, 2008). More importantly,
physical interactions between NF-kB signaling members such as p65 and RelB
with the AhR contribute to immune suppression and altered inflammatory
responses (Camacho et al., 2005; Vogel et al., 2007a; Vogel et al., 2007b; Vogel
and Matsumura, 2008). In vitro AhR activation inhibited p65 nuclear
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translocation, which was implicated in altered DC survival contributing to immune
suppression. TCDD-induced modulation in BMDC differentiation was associated
with decreased RelB levels in BMDCs (Lee et al., 2007). More recently, TCDDmediated induction of immune inhibitory enzyme IDO was suggested to require
both AhR and NF-kB component, RelB (Vogel and Matsumura, 2009). Activation
of the AhR by TCDD elicits active inflammation in different organs. TCDDinduced inflammatory responses have been associated with an increased
production of proinflammatory mediators including TNF-α, IL8, IL-1β and
cycloxygenase 2 (Cox2)(Vogel and Matsumura, 2009). NF-kB proteins play a
critical role in regulating inflammatory responses and interact with the AhR. In an
attempt to elucidate the consequences of RelA/AhR or RelB/AhR interactions on
inflammatory responses, Vogel et al proposed that activated AhR facilitates the
function of RelB, both in the induction as well as resolution of inflammation.
Interaction of the AhR with RelA, on the other hand, dampened the action of
RelA on inflammatory responses (Vogel and Matsumura, 2009). Taken together,
these studies highlight a critical role of the AhR in the regulation of cellular
inflammation via interactions with the NF-kB signaling pathway.
TCDD-induced toxicity in animals: Exposure to TCDD generates a spectrum of
adverse health effects in multiple animals species (Birnbaum and Tuomisto,
2000). Reported TCDD toxicity, mediated by AhR activation in animals ranges
from induction of cachexia, disruption of endocrine pathways, chloracne,
hepatotoxicity, teratogenesis to immune suppression. A cascade of common
toxic effects of TCDD is observed in all animals following exposure. TCDD-
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induced lethality that occurs in weeks is associated with wasting syndrome,
characterized by severe weight loss concomitant with reduction in both muscle
and adipose tissue (Seefeld et al., 1984; Max and Silbergeld, 1987). On a similar
note, thymic atrophy is also another common manifestation of TCDD toxicity and
is characterized by lymphocyte depletion in the thymic cortex (Staples et al.,
1998). TCDD-induced toxicity is also associated with severe a skin condition
characterized by hyperkeratotic and hyperproliferative skin response known as
Chloracne (Birnbaum and Tuomisto, 2000). This acute skin condition has been
reported in cows, horses, ears of rabbit and also on the skin of hairless mice
(Birnbaum and Tuomisto, 2000). Hepatotoxicity is reported in rats and rabbits
following TCDD exposure. Reproductive effects from TCDD exposure have been
documented in mice, rats and monkeys where TCDD is demonstrated to reduce
litter size, fertility and uterine weights (Kociba et al., 1976; Barsotti et al., 1979;
Umbreit et al., 1987). TCDD exposure has been associated with induction of
developmental syndrome in mice characterized by fetal thymic atrophy,
hydronephrosis and cleft palate (Couture et al., 1990a; Couture et al., 1990b;
Birnbaum and Tuomisto, 2000). In chickens, TCDD affects the cardiovascular
system. Additionally, TCDD also targets the nervous system; however,
mechanisms underlying neurotoxic effects of TCDD remain poorly investigated
(Birnbaum and Tuomisto, 2000). Studies have also identified TCDD as a
complete carcinogen in lab animals. Exposure to TCDD at increasing doses
induces cancer in experimental animals and is associated with development of
tumors in the liver, thyroid, respiratory tract and other organs.
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The severity of TCDD toxicity is dependent on multiple factors such as the
animal species, strain, age and gender (Neubert, 1997). Differential sensitivity of
animal species to TCDD is attributed to polymorphisms in the Ah locus (Takashi
Moriguchi 2003). For example, a 10-fold difference in susceptibility to TCDD has
been reported between C57Bl/6 (sensitive) and DBA/2 (resistant) strain of mice
(Dolwick et al., 1993; Ema et al., 1994a; Ema et al., 1994b). C57Bl/6 and Balb/c
express the dominant responsive allele, Ahrb-1 and Ahrb-2, respectively when
compared to the less responsive strain DBA/2 bearing the recessive nonresponsive allele designated Ahrd (Poland and Grover 1990). Similarly, Long
Evans (sensitive) and Han/Wistar rats (resistant) differ in a magnitude of >1000
fold in terms of their susceptibility to dioxins due to a mutation in the Trans
activation domain of the AhR (Takashi Moriguchi 2003).
AhR knockout, mutant and transgenic mice: Generation of AhR knockout and
mutant mice has played an instrumental role in dissecting the AhR-mediated
toxicities from those arising from alternative pathways (Fernandez-Salguero et
al., 1995; Schmidt et al., 1996). AhR knockout mice (AhR-/-) were first created
using gene targeting strategies that inactivated the murine AhR gene by
homologous recombination (Schmidt et al., 1996). The resulting AhR-/- mice were
viable, yet displayed developmental defects in the liver (Schmidt et al., 1996).
Furthermore, AhR-/- mice were protected against a spectrum of TCDD toxicities
ranging

from

hepatomegaly,

thymus

atrophy

and

also

immunotoxicity

(Fernandez-Salguero et al., 1995; Thurmond et al., 2000). Studies have
demonstrated a lack of TCDD effect in AhR KO even at a high dose TCDD
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(2000µg/kg). Also, no TCDD-induced lesions were observed in the kidney, heart,
pancreas, spleen, lymph nodes and uterus in AhR-/- mice following TCDD
exposure, suggesting that the pathologic changes induced by TCDD were AhR
dependent.
Mice harboring a mutation in the AhR nuclear localization (AhRnls/nls) were
also generated to determine whether nuclear DRE-mediated events are essential
for the generation of toxic and developmental effects following AhR activation
(Bunger et al., 2003). These mice express the mutant AhR that is capable of
ligand binding but is unable to translocate to the nucleus and bind the DREs.
AhRnls/nls mice also display defects in liver development and are resistant to
TCDD-induced thymic involution, hepatomegaly and cleft palate formation
(Bunger et al., 2003). Bradfield et al., subsequently developed AhR mutant mice
designated AhRdbd/dbd that are capable of herterodimerizing with ARNT, but
incapable of binding DREs (Bunger 2008). Thus, despite nuclear translocation,
AhRdbd/dbd mice displayed no manifestation of TCDD-induced toxic effects
including, cleft palate, hydronephrosis, hepatomegaly and thymic involution
(Perdew, 2008). To assess the importance of ARNT heterodimerization events in
dioxin-induced toxicities, Walisser et al., generated a hypomorphic or lowexpressing Arnt allele, designated Arnt fxneo. Similar to the AhR-/- mice, ARNT
hypomorphs displayed a patent ductus venousus establishing that ARNT
heterodimerization constituted an essential aspect of AhR developmental
signaling.
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A major manifestation of TCDD immunotoxcitiy in animals is thymic
involution, characterized by decreased CD4+CD8+ T cell numbers and skewing of
thymocyte differentiation to single positive CD8+T cells(Staples et al., 1998;
Nohara et al., 2000). To understand the role of AhR in T cells and its contribution
in TCDD-induced immuotoxicity, Nohara and colleagues generated transgenic
mice that expressed a constitutively active mutant of AhR (CA-AhR) in T lineage
cells (Nohara et al., 2005). These transgenic mice displayed decreased numbers
of thymocytes and an increased percentage of CD8+ T cells, suggesting that AhR
activation in T lineage cell was directly responsible for the thymocyte loss and
altered differentiation.
Lastly, to assess the functioning of human AhR (hAhR), Moriguchi et al.,
created AhR-humanized mice, possessing hAHR instead of mouse AhR.
Decreased responsiveness to TCDD was observed in mice harboring hAhR as
compared

to

DBA/2

AhR.

For

instance,

TCDD

induced

embryonic

hydronephrosis but no cleft palate in maternally-exposed homozygous hAHR
fetuses. Creation of these transgenic mice provides a novel tool not only to better
understand the function of the human AhR but also predict TCDD toxicities in
humans (Moriguchi et al., 2003).
TCDD toxicity in humans: Much of what is known today about TCDD toxicity
comes from populations accidentally exposed to TCDD, workers occupationally
exposed to TCDD or populations living close to toxic waste dumps. Since the first
reported incidence of human exposure to TCDD due to a trichlorophenol reactor
explosion in Nitro, West Virginia, several other accidental exposures have been
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reported. These global incidents of human exposure include but are not limited to
PCB-contaminated rice oil consumption in Japan and Taiwan, an explosion at a
trichlorophenol manufacturing plant in Seveso, Italy, and contamination of a
resident community with tainted waste oil in Missouri (Sweeney and Mocarelli,
2000; Kerkvliet, 2002). Because TCDD has a long half-life in humans and
accumulates at a high rate in the body, manifestation of TCDD-induced toxicities
occurs after prolonged low level, daily exposure. Thus, human exposure to dioxin
is associated with chronic, long-term adverse health effects. Studies have linked
TCDD exposure with symptoms such as chloracne, hyper pigmentation,
metabolic alteration, weight loss, immune suppression, neuropathy, endocrine
dysfunction and perturbations in the gastrointestinal systems.

For example,

temporary hepatomegaly observed in individuals exposed to dioxin in the Seveso
incident was associated with no concomitant elevation in hepatic enzymes
(Sweeney and Mocarelli, 2000). Acute exposure to TCDD is documented to
transiently upregulate liver enzymes such as AST, ALT and gamma glutamyl
transferase (GGT). No association of TCDD to altering cholesterol levels was
found in studies that involved Seveso residents and Vietnam veterans (Sweeney
and Mocarelli, 2000). Similarly, no effect on thyroid function was demonstrated in
studies involving production workers (Suskind and Hertzberg, 1984; Ott et al.,
1994; Calvert et al., 1999).
In stark contrast to the variable reports on the non-cancer toxic endpoints
of dioxins, the carcinogenic potential of TCDD is well accepted within the
scientific community. Epidemiological studies have linked TCDD exposure with
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soft-tissue sarcomas, respiratory system tumors and other cancers including Non
Hogkins lymphoma (NHL), in populations exposed accidentally to high
concentrations of TCDD (Fingerhut et al., 1991). Based on carcinogenicity data
in animal models and epidemiological data, TCDD is listed as a human
carcinogen by the International Agency for Research on Cancer (IARC) (IARC,
1997). However, the mechanisms underlying the human carcinogenic potential of
TCDD need further investigation (Cole et al., 2003; Steenland et al., 2004).
In addition, immunological effects of dioxin exposure are also documented
in humans. While some studies have described no clinical signs of immune
suppression in exposed cohorts, others have documented alterations in serum
IgA, IgG and lymphocyte populations and antinuclear antibodies in exposed
individuals (Ott et al., 1994). For instance a study conducted on 40 Missouri
residents whose adipose TCDD levels ranged from 20pg/g to over 430 pg/g, no
clinical evidence of immune suppression was detected (Webb et al., 1989).
Children exposed to TCDD in the Seveso accident, revealed increased serum
complement

levels,

peripheral

blood

lymphocytes

and

increased

lymphoproliferative responses with no adverse clinical effects (Tognoni and
Bonaccorsi 1982). Increased serum IgA levels were detected in US Air Force
personnel exposed to herbicides (Wolfe et al., 1990). An assessment of
immunologic spectrum of the Vietnam War veterans exposed to Agent Orange
contaminated with TCDD showed decreased plasma IgG and increased IgE
levels in the veterans compared to age-matched healthy controls. Following
activation of their peripheral blood mononuclear cells with polyclonal T cell
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activators, decreased levels of IFN-γ and increased levels of IL-4 and IL-10 were
detected in the veteran group (Kim et al., 2003). Taken together, these studies
demonstrate that TCDD exposure results in dysregulated B and T cell responses
eventually leading to perturbation of immune homeostasis.
Using an in vitro model, several investigators have examined the direct
toxic effects of TCDD on various human leukocyte populations. Neubert et al
reported direct effects of TCDD on T cells and B cell proliferation. Both the
percentage and the number of CD4+ and B cells activated with PWM decreased
following activation with 10-12 and 10-14 M, TCDD concentration respectively
(Neubert et al., 1991). Subsequently, Lang et al., reported no direct effect of
TCDD on human lymphocytes treated with 10-7-10-14 M TCDD in the absence of
stimulation with PMW or anti-CD3. An increase in Cyp1A1 activity, with no effect
on lymphocyte proliferation led the authors to conclude that the immunotoxic
effects do not correlate with Cyp1A1 induction (Lang et al., 1994). Additionally, a
study assessing Cyp1A1 induction in human blood lymphocytes in 10 nonsmoking females showed that concentrations of TCDD necessary to elicit in vitro
induction of Cyp1A1 were much higher than human blood levels in vivo. These
studies concluded that the measurement of Cyp1A1 gene expression levels was
not a suitable marker for assessing human immunotoxicity (van Duursen et al.,
2005).
Taken together, a defined relationship between exposure and impaired
immune status remains unestablished. However, with such varying reports
regarding the effects of TCDD on human health, continued surveillance of
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exposed populations and research is warranted to fully understand the long-term
effects of dioxin exposure. The lack of consistent effects on humans have been
attributed to several factors such as lack of proper exposure documentation,
small study populations, genetic variation between human populations and also
insensitive immunological assays. Therefore, future prospective research
examining the immunotoxic effects of TCDD is warranted. Understanding the
mechanism of action of TCDD in laboratory animals first, will provide a stronger
platform for assessing human health risks. Additionally, it will also allow
identification and development of a novel biomarker that can be applied to
human studies. Nevertheless, considering the spectrum of adverse health effects
generated by TCDD, industries have taken measures to minimize release of
dioxin into the environment.
Animal studies have shown that TCDD toxicities are mediated via the Aryl
hydrocarbon receptor (AhR). Additional studies are needed to completely
understand the physiological role of human AhR as well as its role in TCDD
toxicity. Additionally, using laboratory animals, there is a continuous effort to
elucidate AhR-regulated pathways in mediating TCDD toxicities as discussed in
the following sections.
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TCDD Immunotoxicity
The immune system has been identified as a sensitive target of TCDD
(Luster et al., 1989). Exposure of laboratory rodents to very low doses of TCDD
(1<µg/kg body weight) suppresses the generation of adaptive immunity and
increases the susceptibility to infectious diseases (Kerkvliet et al., 1994). TCDD
primarily exerts its toxic effects by binding and activation of the AhR. The AhR is
expressed in several immune cell populations including macrophages, T cells
and B cells (Crawford et al., 1997). Both the innate and adaptive immune
systems are sensitive to AhR activation by TCDD.
Effects of TCDD on the innate immune system: AhR activation by TCDD
affects innate cell populations such as neutrophils, natural killer cells,
macrophages and DCs (Kerkvliet, 2009). In various experimental models, TCDDtreatment has been linked with neutrophilia. Injection of caesin or sheep RBCs in
TCDD-treated

mice

resulted

in

peritoneal

and

pulmonary

neutrophilia

(Ackermann et al., 1989; Kerkvliet and Oughton, 1993). Neutrophilia was also
reported in the spleen in allograft response to P815 tumor cells and in the lung
following flu infection (Choi et al., 2003; Teske et al., 2005). In the context of flu
infection, neutrophilia occurred independent of classical chemoattracants such as
macrophage inflammatory protein (MIP)-Ia, MIP-2, IL-6, lipopolysaacharideinduced CXC chemokine (LIX) or C5a, but rather AhR expressing cells in the
lung were implicated (Teske et al., 2008). Although, the mechanisms underlying
TCDD-induced neutrophila are not completely understood, AhR has been
demonstrated to be an essential component. Several conflicting studies
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documented the effects of AhR activation in NK cells. For example, the cytolytic
activity of NK cells has been shown to be increased, decreased or unaffected
(Lawrence 2007). Adverse effects of AhR activation on macrophages have
similarly been documented. Although AhR activation does not influence either
macrophage phagocytosis, oxidative burst, or tumor cytolytic function, increased
production of proinflammatory cytokines such as TNF-α and IL-1 have been
identified as mechanism underlying TCDD-induced inflammation (Moos et al.,
1997) (Lawrence 2007). This increase in TNF-α production in human
macrophages was found to be dependent on the AhR-EGFR-Erk pathway
(Cheon et al., 2007) Moreover, AhR activation in macrophages induces
transcriptional gene expression changes via either the CaM kinase or the AhRRelB pathway. TCDD-treatment upregulates mRNA levels for Cyp1b1, IL1b, IL8,
Ccl1, β7-integrin and Ahrr in primary human macrophages, in a CaM kinasedependent manner (Monteiro et al., 2008).

In other studies, AhR-RelB

interactions were implicated in TCDD-induced expression of B cells activating
factor (Baff), B cell chemoattractant (Blc), chemokine (C-Cmotif) ligand 1 (Ccl1)
and Interferon γ response factor (Ifr) in a human macrophage cell line (Vogel et
al., 2007b). Interestingly, these AhR/RelB interactions did not require ARNT
demonstrating the role of non-DRE-mediated effects on TCDD induced
inflammatory responses.
DCs express the AhR constitutively and several studies suggest that
defects in DCs following AhR activation contribute to immune suppression.
Decreased numbers of splenic DCs, as well as increased expression of MHC II,
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CD54, CD40, and CD24 was observed in TCDD-treated mice (Vorderstrasse and
Kerkvliet, 2001). DCs from TCDD-treated mice exhibited higher T cell
proliferative response in a mixed lymphocyte reaction and also produced higher
levels of IL-12. Despite this, TCDD did not alter the ability of DCs to phagocytose
latex beads or present Keyhole Limpet Hemocyanin (KLH) to KLH-specific T cells
suggesting that processing and presentation function were unaffected by TCDD
(Vorderstrasse et al., 2003). Later studies also demonstrated the sensitivity of in
vitro generated DCs to TCDD. TCDD enhanced TNF-α-induced DC maturation
and Fas-mediated apoptotic death (Ruby et al., 2005). Microarray analysis
revealed that TCDD increased expression of several genes including Fadd,
Dff40, Ox40l and caspase 9 in purified DCs, suggesting their involvement in
induction of DC apoptosis following AhR activation (Ruby et al., 2005).
Mechanistically, several investigators have implicated non-DRE mediated events
in the generation of DC dysfunction following TCDD exposure. In this context,
interactions of the AhR with NF-kB signaling pathway have been reported as a
mechanism underlying TCDD-induced alterations in DCs. TCDD was shown to
suppress TNF-α- and CD40-induced NF-kB/Rel activation in vitro (Ruby et al.,
2002). In a separate study, Lee et al., demonstrated TCDD altered the
differentiation of bone marrow-derived dendritic cells (BMDCs), an effect that was
attributed to down regulation of RelB (Lee et al., 2007). These studies suggest
that TCDD-induced alterations in NF-kB signaling contributes to defects in DCs,
leading to immune suppression.
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Effects on adaptive immunity: AhR activation by TCDD induces profound
suppression of the adaptive immune system. Both B and T cells constitutively
express low levels of AhR and require activation to enhance its expression
(Lawrence et al., 1996; Crawford et al., 1997; Marcus et al., 1998)
B cells: Evidence that B cells are directly affected by TCDD is provided by
studies conducted by several labs that show modulation of B cell responses in
vitro by TCDD. Kramer et al., linked TCDD-induced kinase activity and
modulation of intracellular Ca2+ levels in B cell to altered B cell responses
(Kramer et al., 1987). Studies by Luster et al demonstrated for the first time that
TCDD inhibits B cell differentiation into plasma cells in response to TNP-LPS
(Luster et al., 1988). TCDD-induced alterations in Ca2+ levels was also linked
with TCDD-induced suppression of surface Ig, but not CD40-mediated antibody
production (Karras et al., 1996). In other studies, TCDD inhibited µ gene
expression and IgM secretion in a CH12.LX B-cell line (Sulentic 2000). This
inhibition of LPS-stimulated IgM secretion was not noted in the BCL-1 B-cell line
that lacks the AhR (Sulentic 1998). Decreased levels of the human B cell
differentiation marker, CD19, following TCDD exposure were linked to
competition between the AhR and B-lineage–specific activator protein (BSAP)
(Masten and Shiverick, 1995). The suppression of CD19, a key molecule
involved in signaling through the BCR, could underlie suppression of antibody
responses by TCDD (Kerkvliet, 2002).
CD4+ and CD8+ T cells: TCDD triggers thymic atrophy and suppresses the
generation of antigen-specific T cell responses in vivo (Kerkvliet, 2002). TCDD
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decreased both CD4+ and CD8+ T cell function, however debate continues as to
whether T cells are direct or indirect targets of TCDD. While some reports
suggest that T cells are not directly affected by TCDD due to lack of AhR binding
to the consensus DRE in T cells, (Lawrence et al., 1996), other investigators
suggest a direct AhR-dependent effect of TCDD in both CD4+ and CD8+ T cells
(Kerkvliet et al., 2002). CD4+ T cell differentiate into Th17, Th1, Th2 or Treg
subsets. The differentiation into each of these specific subsets is dependent on
the expression of transcription factors such as ROR-γT, GATA and Foxp3 that
are shown to express multiple DREs, respectively (Kerkvliet, 2009). This
observation suggests that the AhR may play a prominent role in specifying T cell
differentiation. In a murine graft-versus-host (GvH) model, TCDD promotes Treg
differentiation in donor CD4+ T cells, as defined by their increased expression of
CD25, CTLA-4 and GITR (Funatake et al., 2005). The same study also
demonstrated that TCDD did not merely expand a natural Treg population in the
donor cells as depletion of natural Tregs from donor population prior to injection
into F1 host did not affect the AhR-mediated generation of Tregs (Funatake et
al., 2005). Interestingly, Foxp3 expression was not detected in AhR-dependent
CD4+CD25+ cells, highlighting the AhR as a novel transcription factor for adaptive
Tregs. Subsequent studies demonstrated AhR-dependent modulation of
numerous genes in TCDD-Tregs including TGFβ-3, CCr4, Bcl3, CTLA-4, IL-10,
GATA-3, Icos, CD28 and genes involved in IL-12 signaling pathway.
Downregulated genes included Tnfsf4 (OX40-L), IL13ra, CD86, Bcl6, IL5, NFkb1
and Ccl5 (Marshall et al., 2008). Recently, ligand-specific AhR activation in T
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cells has been shown to generate Tregs or Th17 cells. These studies
demonstrated AhR activation by TCDD or natural AhR ligand formylindolo[3,2b]carbazole (FICZ) to generate Treg or Th17 cells, respectively (Quintana et al.,
2008; Veldhoen et al., 2008). Cumulatively, these findings suggest that AhR
activation during CD4+ T cell differentiation alters gene expression contributing to
altered T cell fate.
In addition to studies on CD4+ T cells, several investigators have
assessed the effects of AhR activation on CD8+ T cell function using the P815
tumor allograft model and the influenza model (Kerkvliet, 2002; Lawrence et al.,
2006). Using the P815 tumor model, Kerkvliet et al., showed that TCDD did not
affect the normal expansion and activation of CD8+ T cells, but affected their
ability to differentiate into functional cytotoxic T lymphocytes (CTLs). The CD8+ T
cells in TCDD-treated mice initially displayed normal production of IL-2 and IFNγ
that diminished on day 5-6 as compared to vehicle-treated control mice (Kerkvliet
et al., 1996). Various hypothesis emerged to describe the observed suppression
of CTL response such as the induction of TCDD-induced apoptosis and/or
anergy of CD8+ T cells (Prell and Kerkvliet, 1997; Prell et al., 2000). Suppression
of the CTL response in this model was also linked to CD4+ T cells. Since TCDDtreated mice produced higher IL-2 on day 4 and 5 of the P815 response, it was
hypothesized that TCDD-induced excess production of IL-2 by CD4+ T cells
leading to their premature deletion. Such deletion deprived the CD8+ T cells of
cognate CD4+ T cell help, preventing CTL expansion (Kerkvliet, 2002). Further
support for this hypothesis arrived from studies by Jeon and Esser demonstrating
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the existence of 3 DREs in the distal region of mouse IL 2 promoter, suggesting
that TCDD-induced excess IL-2 production by CD4+ T may lead to activationinduced cell death (Jeon and Esser, 2000).
In addition to the P815 tumor model, CD8+ T cell function following AhR
activation has been assessed using a murine model of influenza A infection.
TCDD suppressed clonal expansion and differentiation of influenza virus-specific
CD8+ T cells during primary infection, decreased the number of virus-specific
CD8+ T cells secreting IFNγ, and decreased the number but not the response of
virus-specific memory CD8+ T cells (Head and Lawrence, 2009). TCDD
treatment also decreased the number of CD4+ T cells required for antibody
isotype switching and maintenance of anti-viral CD8+ T cell memory.
Interestingly, recent reports have linked AhR activation in CD8+ T cells with CD8+
Treg development as defined by increased CD25 expression and suppressed
cytolytic activity (Funatake et al., 2008). However, AhR expression in CD4+ T
cells was essential for the generation of CD8+ T regs Overall, these results
suggest that AhR-mediated events impact anti-viral immunity, decreasing the
priming of CD8+ T cells.
AhR activation by ligands other than TCDD: As previously described, the AhR
mediates the toxic manifestation of TCDD and TCDD-like chemicals found in the
environment. However, the AhR is an evolutionarily-conserved receptor
suggesting it’s physiological function may extend beyond mediating toxicities of
environmental pollutants such as TCDD. Corroborating this idea are studies
describing AhR to negatively regulate LPS-induced inflammatory responses in
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macrophages, demonstrating its physiologic role in inflammation (Kimura et al.,
2009). More recently, numerous novel natural AhR ligands ranging from dietary
components such as flavones to bilirubin have been described (Table1-2).
Although several investigators have attempted to assess the impact of AhR
activation by natural ligands, very little is known about the character of these
natural AhR ligands and their role in AhR signaling. Characterizing the effects of
natural AhR ligands and their specific mechanisms in immune cells may provide
insights into the physiological functions of the AhR receptor in the immune
system and help devise strategies by which AhR activation can be therapeutically
exploited.
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Table 1-2: The diverse range of natural and non-TCDD AhR ligands.

Natural and non-TCDD AhR ligands
Parent Category

Examples

Function

Flavones

α-napthaflavone

•

β-napthoflavone

•

Genistein

•
•

Indole-containing
molecules

Benzoimidazole
derivatives

Bilirubin

2-(1’H-indole-3’carbonyl)-thiazole-4carboxylic acid methyl
ester (ITE)
6-formylindolo(3,2-b)
carbazole

•

•

M50367

•
•

M50354

•

VAF347

•

VAG539

•

•
•

Leflunamide

•
•

•

AhR antagonist (Zhang et al.,
2003)
AhR agonist (Zhang et al., 2003)
Suppresses immune and
inflammatory responses
(Verdrengh et al., 2003)
Decreases UV-induced
inflammation(Widyarini et al.,
2001)
AhR agonist but does does not
induce TCDD-induced toxicity
such as cleft palate.
Induces Th17 differentiation
(Veldhoen et al., 2008)
Enhances EAE development
AhR receptor agonist (Morales et
al., 2008)
Suppresses Th2 differentitaion
(Negishi et al., 2005)
Anti-inflammatory and antiallergenic(Hauben et al., 2008;
Lawrence et al., 2008)
Inhibits rejection of pancreatic islet
allografts in Balb/c mice
associated with increased
frequency and survival of CD4+
CD25+Foxp3 T-reg
phenotype.(Hauben et al., 2008)
Inhibits CD4 T cell function in
vitro(Liu et al., 2008; Kerkvliet,
2009).
Suppresses EAE development in
vivo(Liu et al., 2008)
Anti-inflammatory compound used
in treatment of rheumatoid
arthritis.(Herrmann et al., 2000)
Metabolized into A771762, that
inhibits denovo pyrimidine
synthesis and inhibits T cell
proliferation (Williamson et al.,
1995; Dimitrova et al., 2002)
Induces antigen-specific regulatory
CD4+ and CD8+ T cells
(Weigmann et al., 2006).
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HYPOTHESIS
Dendritic cells (DCs) are the primary APCs involved in the activation of
naïve T cells and constitutively express the AhR receptor. DCs are sensitive to
TCDD; however limited information exists on the effects of AhR activation in
these cells. Defects in T cell activation following AhR activation have been linked
to AhR-induced defects in DCs. Previous studies demonstrated loss of splenic
DCs following TCDD-exposure, as well as increased expression of CD54, MHC II
and CD40 (Vorderstrasse and Kerkvliet, 2001; Vorderstrasse et al., 2003).
Interestingly, TCDD did not modulate the ability of DCs to process and present
antigen (Vorderstrasse et al., 2003). Ruby et al., also reported direct effects of
TCDD on the maturation and survival of murine, GM-CSF-derived BMDCs. In
these studies, TNF-α-induced DC maturation and Fas-mediated apoptotic death
was enhanced by TCDD (Ruby et al., 2005). Preliminary data from our laboratory
demonstrated AhR activation by TCDD enhanced DC deletion and generation of
defective T cell responses. TCDD-mediated loss or deletion of antigen-bearing
DCs in the lymph node of mice that received Ag-specific OT II cells was found to
be dependent on AhR expression. In addition, DCs from TCDD-treated mice
produced less IL-12 and IL-18 compared to vehicle-treated mice. Cumulatively,
these studies demonstrate that DCs are direct targets of TCDD-induced toxicity
mediated by AhR activation. These TCDD-induced changes in DCs may
dysregulate an immune response and underlie immune suppression.
Because DCs play a key role in generation of successful T cell-mediated
immunity, clearly defining the potential effects of persistent environmental
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pollutants such as TCDD on their fate and function is important. The overall goal
purpose of this study is to provide in depth characterization of the consequences
of AhR activation on murine DCs. The central hypothesis is that AhR activation
modulates DC fate and function, thereby contributing to TCDD-mediated
immune suppression. The following specific aims using in vivo and in vitro
approaches were designed to address this hypothesis:
Aim 1. To evaluate the effects of TCDD on the fate of naïve DCs. (Chapter 2)
Previous studies conducted by Vorderstrasse and coworkers provided an initial
characterization of the effects of TCDD on murine DCs. In these studies, TCDD
induced a decrease in CD11c+ DCs and also affected the expression of key
surface costimulatory molecules in an AhR-mediated fashion (Vorderstrasse and
Kerkvliet, 2001; Vorderstrasse et al., 2003). In a separate study, TCDD was
reported to enhance the TNF-α-induced maturation of BMDCs rendering them
more sensitive to CD95-mediated apoptosis (Ruby et al., 2005). However, the
effects of TCDD on specific murine DC subsets remains to be defined and the
mechanisms underlying the loss of naïve splenic DCs remain to be elucidated.
We hypothesized that TCDD alters DC homeostasis, resulting in the loss of
DCs in naïve mice.
To perform this investigation, C57Bl/6 mice were gavaged with vehicle or
an immunosuppressive dose of TCDD (15µg/kg). Spleen and lymph nodes were
harvested and assessed for TCDD-induced modulation of DC differentiation
markers. Furthermore, effects of TCDD on the fate of functionally distinct splenic
CD11chigh DC subsets, the CD11chigh CD8α+ DEC205+ and the CD11chigh CD8α–

40

33D1+ cells were assessed. Since TCDD selectively, decreased splenic
CD11chigh DC, we evaluated the role of apoptotic and/or migratory events in
mediating this loss of splenic CD11chigh DCs. The extrinsic apoptotic pathway
was assessed using Fas deficient (lpr/lpr) and FasL deficient (gld/gld) deficient
mice. Alternatively, TCDD-induced migration was evaluated via induction of
CCR7, a prominent chemokine receptor involved in the migration and trafficking
of DCs.
Aim 2. To examine the effects of TCDD on the innate and adaptive immune
function of murine BMDCs and assess whether the effects are mediated
exclusively via Dioxin response elements (DREs) (Chapter 3)
Dendritic cells are hematopoietically-derived cells which can be generated in vitro
from murine bone marrow cells using the growth factor, GM-CSF. Generation of
bone marrow-derived dendritic cells (BMDCs) allows a rapid, convenient
assessment of DCs following exposure to TCDD. Many investigators have
attempted to recapitulate the observed in vivo effects of TCDD exposure on DCs
in an in vitro setting. For instance, studies conducted by Ruby et al., showed that
TCDD-treatment of BMDCs enhanced TNF-α-induced maturation, and also
augmented the CD95-mediated death of BMDCs (Ruby et al., 2004). More
recently, Lee et al., demonstrated TCDD-induced down regulation of RelB mRNA
levels in GM-CSF derived BMDCs (conventional DCs) (Lee et al., 2007).
However, the effects of TCDD on a homogenous, pure population of DCs
remains to be characterized. Additionally, several investigators have linked AhR
activation by TCDD with induction of Tregs and Treg inducing mediators such as
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IDO1, IDO2 and TGF-β3. Despite these studies, it remains to be determined
whether TCDD affects the normal development and function of DCs. Additionally,
it is unknown whether AhR activation induces regulatory DCs that could
contribute to Treg generation. Under the second specific aim TCDD-induced
phenotypic and functional alterations in conventional DCs (GM-CSF derived) will
be examined. We hypothesize that TCDD alters BMDC differentiation and
generates a regulatory phenotype.
To perform this study, inflammatory BMDCs from C57Bl/6 mice were
generated using GM-CSF, in the presence of vehicle (DMSO) or TCDD. TCDDinduced modulation in BMDC differentiation markers, antigen-uptake and TLR
responsiveness was assessed. Furthermore, NF-kB activation profile in these
BMDC cultures was assessed using TransAM NF-κB colorimetric assays. The
functional ability of vehicle-or TCDD-treated BMDCs to interact with CD4+ T cells
in an antigen-specific fashion and influence the development of an adaptive
immune response was tested using an adoptive transfer model. To delineate the
role of the activated AhR in the fate and development of conventional DCs in
vitro, we generated BMDCs from the bone marrow of AhR-/- and AhRnls/nls and
AhRdbd/dbd mice. Bone marrow cells from these mutant mice were cultured in
presence of GM-CSF and vehicle or TCDD (10nM) for 6 days. Non-adherent
cells were harvested and evaluated for TCDD effects on phenotypic DC markers.
Alteration in DC phenotype was compared to naïve C57Bl/6 mice expressing
high-affinity AhR. Additionally, mRNA levels of suppressive T-reg inducing
mediators such as Indoleamine 2,3-dioxygenase (IDO) and TGF-β3 were
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evaluated in BMDCs.
Aim 3: To examine whether AhR-activated BMDCs contribute to the
generation of regulatory T cells (Chapter 4) Results from the previous specific
aim 2 demonstrated TCDD-induced regulatory phenotype in DCs characterized
by increased IDO1, IDO2 and TGF-β3 mRNA levels. We therefore, assessed the
effects of these regulatory DCs on the generation of T regs. We hypothesized
that TCDD-treated BMDCs, displaying a regulatory phenotype induce
adaptive Tregs.
To perform this investigation, ova-peptide loaded, vehicle- or TCDD –
treated BMDCs were cocultured with antigen-specific CD4+CD25- T cells. On day
4, cells were harvested and evaluated. Additionally, an adoptive transfer model
examining the role of LPS-activated TCDD BMDCs in suppressing T cell
activation was employed.
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ABSTRACT
The

environmental

contaminant,

TCDD

(dioxin),

causes

immune

suppression via activation of the Aryl hydrocarbon receptor (AhR). Dendritic cells
(DCs), the professional antigen-presenting cells in the immune system, are
adversely affected by TCDD. We hypothesize that TCDD alters DC homeostasis,
resulting in DC loss in naïve mice. To test this hypothesis, C57Bl/6 mice were
gavaged with either vehicle or TCDD (15 µg/kg). Consistent with previous
reports, TCDD exposure decreased the frequency and number of splenic
CD11chigh DCs on day 7, when compared to vehicle. TCDD increased the
expression of CD86 and CD54, while decreasing the frequency of CD11a and
MHC Class II on the splenic CD11chigh DCs. The frequency of CD40 on
CD11chigh DCs was increased by TCDD. Moreover, TCDD selectively decreased
the CD11chighCD8α-33D1+ splenic DCs subset specialized at activating CD4+ T
cells but did not affect the regulatory CD11chighCD8α+DEC205+ splenic DC
subset. TCDD did not alter the number and frequency of CD11clow splenic DCs,
but decreased their MHC II and CD11a expression. The splenic CD11chigh DC
loss was independent of Fas-mediated apoptosis. Furthermore, CD11chigh DCs
displayed no apoptosis as defined by Annexin V/7-AAD staining. Instead,
increased CCR7 expression on CD11chigh DCs suggested involvement of a
migratory event. Popliteal and brachial lymph node

(PBLNs) CD11c+ cells

displayed elevated levels of MHC II and CD40 but not DC loss following TCDD
exposure. Collectively, this study demonstrates the presence of a TCDD-
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sensitive splenic DC subpopulation in naïve mice, suggesting that TCDD may
induce suppression of T cell-mediated immunity by disrupting DC homeostasis.

Key words: Aryl hydrocarbon receptor; dendritic cells; immunosuppression;
TCDD; apoptosis; CCR7

Abbreviations:

AhR, Aryl hydrocarbon receptor; cells; Ag, antigen; APC,

antigen presenting cell; CCR7, Chemokine receptor 7; CCL19, EBI1 ligand
chemokine/MIP-3β;

CCL21,

secondary

lymphoid

tissue

chemokine

[SLC]/6Ckine; DCs, dendritic cells; IKDC, Interferon producing killer dendritic
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INTRODUCTION
The immune system has been identified as a sensitive target of 2,3,7,8
tetrachlorodibenzo-p-dioxin (TCDD) (Luster et al., 1989). Exposure of laboratory
rodents to very low doses of TCDD suppresses the generation of adaptive
immunity and increases the susceptibility to infectious diseases (Kerkvliet and
Burleson, 1994). TCDD primarily exerts its toxic effects by binding and activation
of the Aryl hydrocarbon receptor (AhR) (Fernandez-Salguero et al., 1996;
Perdew, 2008).
Dendritic cells (DC) are the most potent antigen presenting cells and the
primary immune cells responsible for the activation of naive T cells.

DCs

populate most tissues in mice and can be identified by the expression of the
integrin, CD11c. DCs progress through multiple differentiation stages based on
their activation status. Immature DCs are characterized by expression of low
levels of CD11c, and of co-stimulatory molecules such as MHC II, CD86 and
CD54, but are very efficient at the phagocytosis of antigen. Following activation,
immature DCs migrate to the draining lymph nodes, undergo maturation and
activate naïve T cells leading to generation of antigen-specific, T cell-mediated
immune responses. Mature DCs are CD11chigh but exhibit a decreased capacity
to internalize antigens. The activation, maturation and migration of DCs to T cellrich areas such as lymph nodes can be triggered by phagocytic uptake of
antigens or exposure to pathogen-associated molecular patterns (PAMPs) such
as LPS (Winzler et al., 1997a; Winzler et al., 1997b; Banchereau et al., 2001).
Migration of DCs to lymph nodes is mediated by chemokine receptors such as
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CCR7 (Gunn, 2003; MartIn-Fontecha et al., 2003; Randolph et al., 2005).
Deficiency of CCR7 or its primary ligands CCL19 or CCL21, results in abnormal
lymph node development and dysfunctional leukocyte trafficking (Forster et al.,
1999; Gunn et al., 1999; Mori et al., 2001; MartIn-Fontecha et al., 2003).
DCs exist in a variety of subsets specialized in mediating distinct effector
functions. In the murine spleen, two distinct subpopulations of DCs have been
identified phenotypically by the expression of CD11c: CD11chigh and CD11clow
cells. CD11clow DCs have been characterized to be immature DCs whereas the
CD11chigh DCs are considered mature. Recently, two functionally distinct
CD11chigh DC subsets in the spleen were identified based on their expression of
CD11chighCD8α+DEC205+ and CD11chighCD8α–33D1+ (Dudziak et al., 2007).
CD8α+DEC205+ DCs are specialized at cross-presentation of antigens to CD8+ T
cells and at inducing Foxp3+ regulatory T cells (Dudziak et al., 2007; Yamazaki et
al., 2008). On the other hand, CD8α-33D1+ DCs are more effective at the uptake
of exogenous Ags and subsequent activation of CD4+ T cells.
DCs are sensitive to TCDD, however, limited information exists on the
effects of AhR activation in these cells. Because DCs play a key role in the
generation of successful T cell-mediated immunity, it is important to define the
potential effects of persistent environmental pollutants such as TCDD on their
fate and function. Studies conducted by Vorderstrasse and coworkers provided
an initial characterization of the effects of TCDD on naïve murine DCs. In these
studies, TCDD induced a decrease in CD11c+ DCs and also affected the
expression of key surface co-stimulatory molecules in an AhR-mediated fashion
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(Vorderstrasse and Kerkvliet, 2001; Vorderstrasse et al., 2003). In a separate
study, TCDD was reported to enhance the TNF-α-induced maturation of bone
marrow-derived dendritic cells (BMDCs) rendering them more sensitive to CD95mediated apoptosis (Ruby et al., 2005). However, the effects of TCDD on
specific murine DC subsets remains to be defined and the mechanisms
underlying the loss of naïve splenic DCs remain to be elucidated. In the present
study, we have characterized the fate of distinct DC subsets in the spleen and
lymph nodes of TCDD-treated naïve mice. In addition, we have explored
potential

mechanisms

responsible

for

TCDD-induced

disruption

of

DC

homeostasis in unimmunized mice.

63

MATERIALS AND METHODS:
Animals. 6-8 week old C57Bl/6 mice were purchased from Jackson Laboratory
(Bar Harbor, ML) and maintained in accordance with UM IACUC standards.
Animals were provided rodent chow and tap water ad libitum. Breeding pairs of
AhR knockout mice (AhR-/-) were obtained from Dr. Paige Lawrence (University
of Rochester) and subsequently bred and maintained at UM. C57Bl/6gld/gld mice
(B6Smn.C3-Faslgld) possessing a natural mutation in the Fas Ligand gene,
originally purchased from Jackson Laboratory (Bar Harbor, ML) were generously
provided by Dr. Andrij Holian University of Montana). C57Bl/6lpr/lpr mice (B6.MRL-

Faslpr) possessing a natural mutation in the Fas gene were obtained from
Jackson Laboratory (Bar Harbor, ML). For all experiments, animals were
euthanized by CO2 overdose followed by cervical dislocation.
TCDD exposure. TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) was obtained from
Cambridge Isotope laboratories Inc., (Woburn MA), dissolved in anisole and
diluted in peanut oil. Control mice received vehicle consisting of comparable
doses of anisole and peanut oil. For all experiments, mice were gavaged once
with vehicle or an immunosuppressive dose of TCDD (15 µg/kg) (Kerkvliet et al.,
1996). Animals were sacrificed either on day 5 or day 7 after treatment and
immune tissues harvested for subsequent analyses.
Preparation of Splenocytes. Spleens were harvested and processed as
previously described (Shepherd et al., 2001). Briefly, spleens were processed
between the frosted ends of slides, erythrocytes were depleted by hypotonic lysis
and cells were washed and resuspended in cold HBBS, 5% FBS, supplied with
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20 mM hepes, 50 µg/ml gentamycin and 1.5mM sodium pyruvate (referred to as
cHBSS).
Preparation of Popliteal and brachial lymph nodes (PBLNs). Popliteal and
Brachial lymph nodes were harvested 5 or 7 days after vehicle or TCDD
treatment. Lymph node tissue was processed using the end of a 1 ml syringe and
cell strainer in 5 ml of cHBSS. The cell suspension was centrifuged at RT at
1200rpm for 10 minutes. The supernatant was discarded and cells resuspended
in 1 ml of cHBSS.
Flow Cytometry. Immune cells were stained for FACS analyses as previously
described (Shepherd et al., 2001). Rat, hamster or mouse IgG block was added
to aliquots of prepared leukocytes for 10 minutes on ice to prevent non-specific
binding. Splenocytes were stained for 10 minutes on ice with monoclonal
antibodies (mAb) from Pharmingen (San Diego, CA): CD11c (HL3), CD11b
(M1/70), B220 (RA3.6B2), Ly6C (AL-21), CD11a (2D7), MHC II (2G9), CD86
(GL1) and CD40 (3/23); Miltenyi Biotec (CA): DEC205 (NLDC-145); Biolegend
(San Diego, CA): CD11c (N418), CCR7 (4B12), CD8 (53-6.7), CD54 (YN1/1.7.4);
and eBioscience (San Diego, CA): 33D1. Similarly, PBLNs were stained for 10
minutes on ice with mAbs to CD11c (N418), CD11a (2D7), MHC II (2 G9), CD86
(GL1), CD40 (3/23) and CCR7 (4B12). All mAbs used were titrated for optimal
concentration and appropriately-labeled, isotype-matched mAbs were used as
controls. Acquisition of 100,000-300,000 events from freshly prepared cells was
performed using a FACS Aria flow cytometer (BD biosciences) and analyzed by
BD FACS Diva software (Version 4.0).
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For detection of apoptosis, immune cells were stained with Annexin V and
7AAD as per the manufacturer’s instructions (BD Pharmingen). After surface
staining for CD11c, cells were resuspended in 1 X Annexin binding buffer,
incubated with Annexin-V FITC for 15 minutes at room temperature in the dark,
followed by addition of 7AAD for 10 minutes and analyzed as described above.
For sorting CD11chigh and CD11clow splenic DCs, mice were injected i.p.
once daily for l0 consecutive days with 20µg

human recombinant Flt3L

(Peprotech Inc., New Jersey) as previously described (Maraskovsky et al., 1997;
Pulendran et al., 1997). Mice were harvested on day 11, splenocytes were
prepared, stained with CD11c and purified using anti-PE beads from Miltenyi
Biotec (CA). Cells were sorted in sterile sorting buffer using FACS Aria flow
cytometer for CD11chigh (>92% purity) and CD11clow populations (>86% purity).
Western blotting. Lysates were prepared from FACS-sorted splenic CD11chigh
and CD11clow DCs. Protein concentrations from cell lysates were determined
using the BCA assay (Pierce, IL). Protein lysates (17µg per lane) were loaded on
a 4-12 % SDS PAGE gel (Invitrogen, CA) and transferred onto PVDF membrane
(Biorad, CA). Anti-AhR antibody (Biomol, PA) was used to specifically detect
murine AhRb at a dilution of 1:5000 at 4°C overnight. After washes in TBST

(Tris-buffered saline Tween-20), horseradish peroxidase conjugated goat
anti-rabbit IgG (Jackson Immuno research laboratories) was used at a dilution of
1:1000 for 1 hour at room temperature. The membrane was washed and
incubated in enhanced chemiluminiscence reagent (ECL: Amersham, New
Jersey). Membranes were visualized and analyzed using Fuji Film Image Reader
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(Las 3000, Version 2). Similiarly, the membrane was also probed for β-actin
using anti-β actin antibody (Abcam, MA) and horseradish peroxidase conjugated
rabbit anti-mouse IgG (Southern biotech, Alabama) as the secondary antibody.
Statistical analysis.

Results are presented as the mean ± SEM of 6 mice

unless otherwise indicated. For all experiments, an unpaired t test was used to
compare the mean of the vehicle-treated group to the mean of the TCDD-treated
group. Values of p ≤ 0.05 were considered statistically significant.
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RESULTS
DC subpopulations in the peripheral immune tissues. Based on the
expression of CD11c, the murine marker for DCs, splenocytes and PBLNs differ
in their DC composition. Two distinct subpopulation of DCs, referred to as
CD11chigh and CD11clow exist in the mouse spleen (Figure 2-1). In contrast, the
peripheral lymph nodes contain a uniform CD11c+ population with no discernible
CD11chigh and CD11clow DCs (Figure 2-1). DCs representing an immature
phenotype, display low levels of co-stimulatory molecules such as MHC II and
decreased capacity to activate naïve T cells. On the other hand, mature APCs
mostly display increased levels of costimulatory molecules and are highly
efficient at T cell stimulation (Sato and Fujita, 2007).
Effects of TCDD on naïve splenic DC subpopulations. To assess the potential
sensitivity of DC subsets to TCDD, AhR protein levels were evaluated in purified
CD11chigh and CD11clow splenic DCs. As shown in Figure 2-1B, both splenic DC
subpopulations constitutively express comparable levels of AhR. Consistent with
previous studies, TCDD exposure caused a decline in the percentage and
number of CD11chigh DCs recovered from the spleen on day 7 (Figure 2-2A+2B)
(Vorderstrasse and Kerkvliet, 2001). In the majority of experiments, TCDD had
no effect on the percentage or number of splenic CD11clow DCs on 7 (Figure 22C+2D).
Costimulatory molecule expression on naïve splenic DCs from TCDDtreated mice. Expression of co-stimulatory molecules such as MHC II, CD86,
CD40 and CD11a reflect the activation and/or maturational status of DCs.
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Figure 2-1

Figure 2-1. (A) CD11c expression on DCs from peripheral immune tissues.
Histograms represent two distinct populations of dendritic cells in unimmunized
mice, CD11chigh and CD11c

low

cells in the spleen or lymph nodes. (B) AhR

protein levels in splenic CD11chigh and CD11clow DCs. Lysates were prepared
from Flt3L-treated C57Bl/6 mice. Spleens were harvested on day 11 and DC
lysates were prepared from FACS-sorted CD11chigh and CD11clow DCs. Purified,
non-adherent bone marrow-derived dendritic cells (BMDCs) were used as a
positive control for the expression of AhR. Whole cell lysates were evaluated by
Western blotting for AhR and β-actin as described in the Materials and Methods.
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Figure 2-2
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Figure 2-2. TCDD induces a loss of splenic CD11chigh but not CD11clow DCs.
C57Bl/6 mice were treated with vehicle or TCDD (15µg/kg). Spleens were
harvested on day 7, processed and phenotyped by FACS analysis as described
in Materials and methods. Bar graphs represent the percentage and numbers of
splenic CD11chigh (A, B) and CD11clow (C, D) DCs as determined by flow
cytometry. Data represent means ± SEM from 6 mice per treatment group from
4 independent experiments. * indicates p ≤ 0.05 for the comparision between
vehicle- and TCDD-treated mice, respectively.
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Therefore, several key activation markers were evaluated on both splenic CD11c
populations. TCDD increased the expression of CD86, CD54 and the frequency
of CD40 on CD11chigh DCs. The frequency of both MHC II and CD11a on
CD11chigh DCs was downregulated by TCDD. CD11clow cells from TCDD-treated
mice displayed a decrease in MHC II and CD11a frequency when compared to
vehicle-treated controls. Although there was no effect on CD40, expression of
both CD86 and CD54 on CD11clow DC increased following TCDD exposure
(Table 2-1).
Because distinct DC subsets with unique functions have been recently
characterized in the mouse spleen, we examined the effects of TCDD on these
DC subsets. CD11chigh DCs expressing the phenotypic markers CD8α+DEC205+
or CD8α-33D1+ occupy different anatomical positions in the spleen and mediate
distinct effector functions (Dudziak et al., 2007). TCDD caused a 40 percent
reduction in the number of splenic CD11chigh CD8α- 33D1+ DCs on day 7 but not
on day 3 or 5 (Table 2-2 and data not shown). This effect was dependent on the
expression of the AhR as no loss of CD11chighCD8α-33D1+ DCs occurred in AhR
knockout mice exposed to TCDD (Table 2-2). In contrast, the number of
CD11chigh CD8α+ DEC205+ DCs subset was unaffected by TCDD. Consistent
with the study by Vorderstrasse and coworkers, an upregulation of CD8α+ by 10
percent was observed on CD11chigh DCs isolated from TCDD-treated mice (data
not shown).
Additionally, splenic CD11clow cells can be segregated phenotypically into
two subsets – plasmacytoid DCs (pDCs), which are CD11clowCD11b-Ly6C+B22
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TABLE 2-1
Effects of TCDD on the expression of key accessory molecules on splenic DCsa

CD11c high DCs

MHC II

CD86

CD40

CD11a

CD54

a

CD11c low DCs

Vehicle

TCDD

Vehicle

TCDD

Percentage

99 ± 0.2

96 ± 0.6*

80 ± 0.5

75 ± 0.7*

MFI

5228 ± 231

5411 ± 301

1478 ± 77

1298 ± 105

Percentage

53 ± 3

56 ± 2

53 ± 1.6

54 ± 1.2

MFI

1769 ± 64

2174 ± 163*

1170 ± 9

1379 ± 79*

Percentage

58 ± 3

70 ± 4*

36 ± 1.3

33 ± 1.8

MFI

546 ± 21

610 ± 46

870 ± 38

758 ± 54

Percentage

96 ± 0.2

82 ± 0.5*

92 ± 0.6

86 ± 0.3*

MFI

3912 ± 287

4505 ± 428

3906 ± 397

4305 ± 173

Percentage

95 ± 0.2

95 ± 0.3

89 ± 0.5

92 ± 0.6

MFI

4450 ± 302

5848 ± 540*

2518 ± 75

3013 ± 165*

C57Bl/6 mice were treated with TCDD (15µg/kg) or vehicle. On day 7, spleens

were harvested and processed as described in the Materials and Methods.
Expression of activation markers was determined by gating on the CD11chigh and
CD11clow DCs. Percent positive expression (%) and mean/median fluorescence
intensity (MFI) was determined for each activation marker. Data represent the
mean ± SEM of 5-6 mice/treatment and is representative of 2 independent
experiments * indicates p ≤ 0.05 for the comparision between vehicle- and
TCDD-treated mice, respectively.
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TABLE 2-2
Effects of TCDD on splenic DC subsetsa
Vehicle
AhR

+/+

-/-

AhR

a

high

CD11c

high

CD11c

TCDD

CD8α+DEC205+DCs (x105)

3.2 ± 0.2

2.7 ± 0.7

CD8α- 33D1+DCs (x105)

6.5 ± 0.6

3.7 ± 0.9*

CD8α+DEC205+DCs (x105)

6.1 ± 0.6

6.9 ± 1

CD8α- 33D1+DCs (x105)

5.5 ± 0.7

5.3 ± 0.5

C57Bl/6 mice (AhR+/+) and AhR knockout (AhR-/-) mice were treated with vehicle

or TCDD and 7 days later splenic DC subsets were prepared and analyzed as
described in the Materials and Methods. Data represent the mean ± SEM from
four to five mice/treatment. * indicates p ≤ 0.05 for the comparision between
vehicle-and TCDD-treated mice, respectively.
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and Interferon-producing killer DCs (IKDCs), which express CD11clowCD11bLy6C-B220+. In our studies neither percentages nor the numbers of splenic pDCs
or IKDCs were affected following TCDD exposure of naïve mice (data not
shown).
Effects of TCDD on the fate of splenic DCs in naive mice. Because TCDD
selectively decreased CD11chigh DCs in the spleen, we next investigated potential
mechanisms responsible for this decline. We hypothesized that TCDD-induced
decreases in the splenic CD11c high cells may be due to at least two outcomes:
(a) increased DC death via apoptosis, or (b) increased DC emigration out of the
spleen.
Fas-FasL interactions have been implicated in the TCDD-mediated death of
various immune cells including BMDCs (Rhile et al., 1996; Camacho et al., 2001;
Camacho et al., 2002; Dearstyne and Kerkvliet, 2002; Ruby et al., 2005).
Therefore, we examined the potential role of Fas and FasL in the TCDD-induced
loss of splenic CD11chigh DCs. To evaluate this pathway, unimmunized C57Bl/6
lpr/lpr

or C57Bl6

gld/gld

mice were treated with vehicle or TCDD for 7 days. As

shown in Figure 2-3, TCDD treatment decreased both the percentage and
number of splenic CD11chigh DCs when compared to vehicle-treated controls, in
both the Fas–and FasL-deficient mice, respectively. In a separate experiment,
apoptosis was directly evaluated in splenic DCs from wild-type C57Bl/6 mice on
day 5 following TCDD exposure using two well-characterized markers of
apoptosis, Annexin V and 7AAD. TCDD had no effect on the early or late
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Figure 2-3
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Figure 2-3. The number and percentage of splenic CD11chigh DCs in lpr and
gld animals are decreased following TCDD exposure. Non-immunized
C57Bl/6

lpr/lpr

mice (A, B), or C57Bl/6

gld/gld

mice (C, D) were treated with vehicle

or TCDD (15µg/kg) and the numbers of resident DCs in the spleen were
determined on day 7. Data represent the means ± SEM from 5-6 mice per
treatment group and are representative of two independent experiments for
C57Bl/6lpr/lpr and one experiment for C57Bl/6gld/gld mice. * indicates p ≤ 0.05 for the
comparision between vehicle- and TCDD-treated mice, respectively.
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apoptotic staining profiles of splenic CD11chigh cells when compared to controls
(Table 2-3).
DCs reside in the periphery and upon encounter with antigen, undergo
maturation. Maturation of DCs is characterized by phenotypic changes including
the induction of the chemokine receptor CCR7 (Sallusto et al., 1998; Forster et
al., 1999; Gunn, 2003; Scandella et al., 2004; Randolph et al., 2005; SanchezSanchez et al., 2006). Expression of this receptor allows DCs to home to T cellrich areas in draining lymph nodes (Cyster, 1999; Scandella et al., 2002;
Scandella et al., 2004). We hypothesized that a decrease in splenic CD11chigh
DCs could be due to CCR7-mediated migration. To address this hypothesis, the
expression of CCR7 was evaluated on splenic DCs to explore the possibility that
increased migration might underlie the TCDD-induced decline of splenic
CD11chigh cells. CCR7 expression was increased on splenic CD11chigh DCs in
mice on day 5 following TCDD-treatment (Figure 2-4). CCR7 expression on
CD11clow DCs was unaffected by TCDD (data not shown).
DCs in the peripheral lymph nodes are affected by TCDD exposure.
Because TCDD affects homeostasis of splenic DCs, we next examined if DCs
that reside in peripheral lymph nodes are also affected by TCDD. We evaluated
the effects of TCDD exposure on DCs in two sets of peripheral lymph nodes, the
popliteal and brachial lymph nodes. In contrast to the spleen, the peripheral
lymph nodes in mice contain a uniform CD11c+ DC population with no discernible
CD11chigh and CD11clow DCs (Figure 2-1). TCDD did not affect the frequency or
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TABLE 2-3
Exposure to TCDD does not induce apoptosisa

a

Vehicle

TCDD

% Early apoptosis

5.5 ± 0.3

5.3 ± 0.6

% Late apoptosis

5.6 ± 0.4

5.0 ± 0.2

C57Bl/6 mice were treated with TCDD (15µg/kg) or vehicle for 5 days and

spleens were harvested, processed and stained for expression of

CD11c,

Annexin V and 7AAD as described in Materials and Methods. Mature DCs were
identified by gating on the CD11chigh cells from vehicle- and TCDD- treated mice.
Early apoptosis (Annexin V+/ 7 AAD-) and late apoptosis (Annexin V+/7AAD+)
was evaluated. Data represent the mean ± SEM from 4-5 mice/ treatment.
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Figure 2-4

Figure 2-4. TCDD increases CCR7 expression on splenic CD11chigh DCs.
C57Bl/6 mice were treated with vehicle or TCDD. On day 5, spleens were
harvested and processed for flow cytometric analysis as described in the
Materials and Methods. Representative histograms depict CCR7 expression
gated on CD11chigh cells from Vehicle- (A) or TCDD-treated mice (B). Values
shown are mean ± SEM for 4-5 mice per treatment group and are representative
of two independent experiments. * indicates p ≤ 0.05 for the comparision
between vehicle- and TCDD-treated mice, respectively.
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the number of CD11c+ cells in the popliteal and brachial lymph nodes on day 7
(Figure 2-5). As shown in Table 2-4, TCDD exposure enhanced expression of
MHC II and CD40 but did not affect the expression of CD86 and CD11a or alter
the percentage of CD11c+ DCs that expressed these costimulatory molecules in
the peripheral lymph nodes. Interestingly, on day 5 and 7 following treatment,
CD11c+ DCs in the popliteal and brachial lymph nodes of TCDD-treated mice
expressed increased levels of CCR7 (Figure 2-6 and data not shown).
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Figure 2-5
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Figure 2-5. Effects of TCDD on DCs in the peripheral lymph nodes. The
percentages and number of CD11c+ DCs in the popliteal and brachial lymph
nodes were determined from mice treated with TCDD (15µg/kg) or vehicle for 7
days. Lymph nodes were harvested and DCs analyzed by flow cytometry as
previously described in the Materials and Methods. Data represent the mean ±
SEM from 4-6 mice per treatment group. * indicates p ≤ 0.05 for the comparision
between vehicle- and TCDD-treated mice, respectively
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TABLE 2-4
Effects of TCDD on the expression of accessory molecules on DCs from
peripheral lymph nodesa
CD11c+ DCs

a

Vehicle

TCDD

MHC Class II MFI

1803 ± 13

2828 ± 79*

CD86 MFI

3961 ± 271

4611 ± 386

CD40 MFI

814 ± 32

1074 ± 18*

CD11a MFI

2846 ± 114

2706 ± 89

C57Bl/6 mice were treated with TCDD or vehicle for 7 days and lymph nodes

were harvested and processed for flow cytometric analysis. For each activation
marker, results were generated by gating on the CD11c+ DCs from vehicle- and
TCDD-treated mice to determine the mean/median fluorescence intensity (MFI).
Results are representative of two independent experiments and the data
represent the mean ± SEM from 3 mice/treatment. * indicates p ≤ 0.05 for the
comparison between vehicle- and TCDD-treated mice, respectively.
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Figure 2-6

Figure 2-6. Expression of CCR7 is increased on DCs from lymph nodes
following TCDD exposure. On day 5 following exposure to vehicle or 15 µg/kg
TCDD, lymph nodes were harvested and analyzed by flow cytometric analysis as
previously described. Representative histograms depict CCR7 expression on
CD11c+ cells in mice treated with vehicle (A) or TCDD (B). Values represent the
mean ± SEM of 5 mice per treatment group. * indicates p ≤ 0.05 for the
comparison between vehicle- and TCDD-treated mice for 2 independent
experiments.
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DISCUSSION
DCs play an important role in both the innate and adaptive arms of the
immune system. They are professional antigen presenting cells, which regulate
induction of T cell-mediated immunity by providing processed antigen to naïve T
cells. The effects of TCDD exposure on distinct DC subsets in the spleen and the
lymph nodes have not been previously examined. In our experiments we have
evaluated the effects of TCDD on naïve splenic DCs- both CD11chigh and
CD11clow cells, in addition to naïve DCs in the peripheral lymph nodes. Both
splenic DC subpopulations constitutively express AhR and therefore expected to
be sensitive to TCDD.
Dendritic cells exist in various differentiation stages referred to as
immature, mature and activated cells, which can be characterized phenotypically
by their varying expression of the costimulatory molecules MHC II, CD86 and
CD40. The seminal publication by Vorderstrasse et al., showed that oral
administration of TCDD induced a loss of splenic CD11c+ DCs in naïve mice
(Vorderstrasse and Kerkvliet, 2001). Importantly, this study utilized low-density
gradient separation in the isolation of DCs. This procedure selects for a distinct
DC subpopulation from immune tissue and also affects DC activation. However,
consistent with these findings, TCDD decreased the frequency and number of
CD11c+ DC. This decline was concomitant with modulation of MHC II, CD11a,
CD40 and CD86 on the remaining CD11c+ DCs in the spleen. Polarization of T
cell differentiation into a Th1 or Th2 response can be significantly affected by the
nature of the DC subset interacting with the T cell. A recent study conducted by
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Dudziak and colleagues, identified two distinct CD11chigh splenic DC subsets in
mice based on their expression of select phenotypic markers: CD8α+ DEC205+
DCs and CD8α- 33D1- DCs (Dudziak et al., 2007). These two distinct DC subsets
differ in anatomical location and possess different effector functions (Vremec et
al., 1992; Dudziak et al., 2007) The CD8α+DEC205+ DCs found in the splenic
pulp specialize in cross presentation of exogenous Ags to CD8+ T cells and have
recently also been implicated in the generation and maintainance of splenic
Tregs (Yamazaki et al., 2008). Present in the mouse spleen, this splenic DC
subset specializes in uptake of exogenous Ags and the activation of CD4+ T cells
via MHC II molecules (Dudziak et al., 2007). Our results demonstrate the
selective effects of TCDD in mediating a decline in the splenic CD11chigh CD8α33D1+ population, which are vital for the activation of CD4+ Th1 helper cells. The
selective loss of this CD4+ T cell activating splenic DC subset, with the
concomitant retention of the suppressive Treg-inducing CD8α+DEC205+ splenic
CD11c population by TCDD may predispose naïve mice to be more susceptible
to blood borne, extracellular pathogens and account for suppressed CD4 T cell
reponses following TCDD exposure. However, further studies are necessary to
specifically evaluate the functional capacity of the splenic DC subsets in
response to extracellular antigens in TCDD-treated mice. Several investigators
have linked TCDD-induced immunesuppression with induction of Tregs. AhR
activation leads to generation of apadtive Tregs (Funatake et al., 2005).
Additionally, Vogel et al., have demonstrated increase in Treg marker Foxp3 in
spleen of TCDD-treated mice (Vogel et al., 2008). Our present findings provide
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suggestive evidence that disruption of DC homeostasis following AhR activation
may contribute to the generation of Tregs and subsequent immune suppression.
In contrast to the CD11chigh cells, TCDD did not alter the frequency or the
numbers of splenic CD11clow DCs. However, alteration of activation markers such
as MHC class II in CD11clow DCs following exposure to TCDD suggests a
modulation in the differentiation status of these cells. CD11clow DCs can be
phenotypically and functionally characterized into at least two distinct
populations, the IKDCs and pDCs. A tolerogenic function has been assigned to
the pDC population in mice (Rutella et al., 2006). Tolerogenic DCs can induce
the generation and maintenance of antigen-specific unresponsiveness in central
and peripheral immune tissues (Steinman et al., 2003). It is thereby possible that
the immunosuppressive effects of TCDD on T cell activation may be attributable
to changes in the number and frequency of tolerogenic DCs. Contrary to our
expectations, both the frequency and the number of pDCs were unaffected by
TCDD. Collectively in the spleen, TCDD decreased the immunostimulatory
subset of DCs but did not affect the tolerogenic DCs, essentially increasing their
relative frequency after 7 days of exposure.
In sharp contrast to spleen, TCDD did not affect the number or frequency
of DCs in the lymph nodes. It did however alter their expression of co-stimulatory
markers such as MHC Class II and CD40. This modulation is reflective of
alteration of the steady state differentiation status of DCs in lymph nodes upon
TCDD exposure and establishes that TCDD, either directly or indirectly, has
effects in the peripheral lymph nodes. Modulation of DC differentiation may alter
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their functional abilty to interact with T cells and generate an activating immune
response.
Exposure to TCDD has been reported to enhance cellular death in several
leukocyte populations. Fas (CD95), a member of the TNF family is expressed on
the surface of DCs as well as other immune cells. Upon binding to Fas ligand
(CD95L), a series of downstream signaling cascades leads to the activation of
terminal effector caspases and ultimately apoptosis (Adachi et al., 1993; Nagata
and Golstein, 1995; Peter and Krammer, 1998; Scaffidi et al., 1998; Lenardo et
al., 1999; Dearstyne and Kerkvliet, 2002). Moreover, Fas-FasL interactions have
been implicated in the TCDD–induced loss of various immune cells including T
cells and DCs. (Rhile et al., 1996; Kamath et al., 1999; Camacho et al., 2001;
Dearstyne and Kerkvliet, 2002; Camacho et al., 2005; Ruby et al., 2005). We
used Fas- deficient (lpr/lpr) and FasL-deficient (gld/gld) mice, defective in this
extrinsic apoptotic pathway, to evaluate the possible involvement of Fas/FasL
interactions in the decline of naïve splenic CD11chigh DCs by TCDD. Splenic
CD11chigh DCs in both the gld and lpr mice declined in a manner similiar to that
observed in the wild-type mice following TCDD exposure, suggesting that Fasmediated apoptosis is not responsible for the loss of splenic CD11chigh DCs in
naïve mice. Collectively, these studies suggest that the TCDD-induced loss of
naive splenic CD11chigh DCs is independent of Fas-FasL interactions.
Additionally, no evidence of TCDD-induced apoptosis was detected in the
CD11chigh DCs using Annexin V and 7-AAD on day 5 following TCDD exposure
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of naïve mice. Taken together, our results demonstrate an overall lack of
apoptosis in splenic CD11chigh DCs following exposure to TCDD.
Alternatively, the decline in splenic CD11chigh DCs upon TCDD exposure
could be due to induced emigration. CCR7 is a chemokine receptor that plays a
prominent role in the migration/trafficking of immune cells including DCs. This
receptor specifically binds two ligands, CCL21 and CCL19, which are expressed
constitutively by endothelial cells in the lymphatic vessels and high endothelial
venules. Immature DCs, which comprise the majority of DCs in an unimmunized
animal, also express this receptor and migrate to the lymph nodes (SanchezSanchez et al., 2006). However, in the absence of danger signals, these DCs
contribute to peripheral tolerance against self-antigens (Scandella et al., 2004;
Sanchez-Sanchez et al., 2006). Premature induction of migration, in the absence
of danger signals may alter DC homeostasis in the periphery. Specifically for
DCs, CCR7 expression is increased following activation. Interestingly, CCR7
expression was enhanced on the splenic CD11chigh DCs following TCDD
exposure, suggesting the possibility that these cells were aberrantly being
induced to emigrate out of the spleen. Also, CCR7 expression increased on DCs
that resided in the peripheral lymph nodes in unimmunized mice treated with
TCDD. The possibility exists that TCDD induces the release of proinflammatory
cytokines by resident cells in the lymph nodes leading to upregulation of CCL21
on the lymphatic endothelium. Upregulation of a ligand for CCR7 could then
induce chemotaxis of splenic DCs into the lymph nodes. However, no alteration
in the frqeuency or the numbers of lymph node DCs was observed with TCDD. It
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is possible that increased CCR7 expression on lymph node DCs could induce
their emigration to the source of CCR7 ligands. The role of TCDD-induced
increased CCR7 expression on lymph node DCs remains to be identified.
However, additional experiments are necessary to establish if TCDD-induced
migration of DCs is dependent on alterations in the expression of CCR7 or its
ligands.
A seemingly plausible model emerges considering the progressive
increase in CD11c expression, along with the modulation in the activation
markers as DC differentiation proceeds (Figure 2-7). It is possible that TCDD
selectively affects a subset of splenic CD11chigh DCs increasing the CCR7
expression on these DCs, ultimately leading to their emigration out of the spleen.
Because

DCs

acquire

enhanced

migratory

abilities

as

they

undergo

differentiation, aberrant migration of splenic DCs may underlie the ability of
TCDD to disrupt DC homeostasis in lymphoid organs. Alteration of DC
differentiation and homoestasis by TCDD may generate dysfunctional DCs
leading to immune suppression.
In conclusion, we have shown that TCDD affects DCs homeostasis by
selectively decreasing a distinct subset (CD11chigh CD8α- 33D1+ DCs) in the
splenic tissue of naïve mice. This loss of mature DCs was not attributed to Fasmediated apoptosis. Instead, upregulation of CCR7 on the splenic CD11chigh DCs
provides suggestive evidence that migration of these DCs may be playing a role
in TCDD-induced loss of splenic CD11chigh DCs. In addition, our results
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demonstrate increased activation of DCs in both the spleen and the lymph nodes
following exposure of naïve mice to TCDD.
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Figure 2-7. Schematic diagram of the effects of TCDD on splenic CD11chigh
DCs.
A) In naïve condition, splenic CD11chigh DC subsets exist in a homeostatic
balance. The CD11chighCD8-33D1+ DCs, represented in gray reside in the
marginal zone and interact with CD4+ T cells. The CD11chighCD8+DEC205+ DCs
residing in the splenic pulp area are specialized at inducing/maintaining Tregs. B)
Following TCDD exposure the DC homeostasis balance is perturbed. TCDD
induces the loss of CD11chighCD8-33D1+ DCs and retention of Treg-inducing
CD11chighCD8+DEC205+ DCs.
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ABSTRACT
Aryl hydrocarbon receptor (AhR) activation by its prototypical ligand 2,3,7,8tetrachlorodibenzo-p-dioxin (TCDD) induces immune suppression. Dendritic cells
(DCs) are key antigen presenting cells governing T cell activation and
differentiation. However, the consequences of AhR activation in DCs are not fully
defined. We hypothesize that AhR activation alters DC differentiation and
generates dyfunctional DCs. To test this hypothesis, inflammatory BMDCs were
generated in the presence of vehicle or TCDD. TCDD decreased CD11c
expression but increased MHC class II, CD86 and CD25 expression on BMDCs.
The AhR ligands 6-formylindolo[3,2-b]carbazole (FICZ) and 2-(1H-Indol-3ylcarbonyl)-4-thiazolecarboxylic acid (ITE) elicited similar effects to TCDD on
BMDCs. The effects were strictly AhR-dependent but not exclusively DREmediated. TCDD downregulated LPS- and CpG-induced NF-kB p65 levels and
induced a trend towards upregulation of RelB levels in BMDCs. Induction of
indoleamine 2,3–dioxygenase (IDO) and TGF-β3 has been implicated in the
generation of Tregs following AhR activation. AhR activation by TCDD increased
IDO1, IDO2 and TGF-β3 mRNA levels in BMDCs as compared to vehicle.
Interestingly, despite the induction of a regulatory phenotype, TCDD-treated
BMDCs failed to suppress antigen-specific T cell activation.
Keywords: Aryl hydrocarbon receptor (AhR); dendritic cells (DCs); 2,3,7,8tetrachlorodibenzo-p-dioxin
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INTRODUCTION
The Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription
factor mediating the toxic effects of environmental pollutants such as TCDD.
Following ligand binding, the AhR translocates into the nucleus, where in
conjunction with its dimeric partner the Aryl hydrocarbon receptor nuclear
translocater (ARNT) it binds to dioxin response elements (DREs) in target genes.
AhR activation has been recognized as the prime mechanism by which
environmental pollutants such as dioxins exert their adverse effects. The
prototypical dioxin, 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD), is a high
affinity, exogenous AhR ligand. Exposure to very low doses of dioxin produces
immune suppression via activation of the AhR in many animal species, making
them highly susceptible to infectious diseases and cancer (Kerkvliet, 2002). More
recently, various tryptophan metabolites such as 6-formylindolo[3,2-b]carbazole
(FICZ) and 2-(1H-Indol-3-ylcarbonyl)-4-thiazolecarboxylic acid (ITE) have been
described as high-affinity natural AhR ligands (Oberg et al., 2005; Henry et al.,
2006). Few studies have examined the effects of these natural AhR ligands on
the immune system. Initial studies demonstrated that FICZ, a high affinity AhR
agonist induced Th17 differentiation and inhibited Treg development by TGF-β
(Quintana et al., 2008). Contrasting their findings, Kimura et al demonstrated
Treg induction by TGF-β that was enhanced when the AhR was activated by
TCDD or FICZ (Kimura et al., 2008). FICZ also increased the expression of
CD86 on human U937 monocyte-derived DCs (Veldhoen et al., 2008; Vogel et
al., 2008) Studies conducted by Henry et al., showed that similar to TCDD, ITE
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alters thymocyte differentiation in vitro (Henry et al., 2006). However, the effects
of these natural AhR ligands on dendritic cells have not been previously
described.
Dendritic cells (DCs) are key immune cells that bridge the gap between
innate and adaptive immunity. Progressive differentiation of a DC is
characterized by upregulation of MHC II and costimulatory molecules such as
B7-2 (CD86) (Sato and Fujita, 2007). In addition to activating T cells, DCs
constitute part of the first line of defense against invading pathogens and play a
critical role in the generation of effective innate immunity to pathogenic
challenge. The prime innate functions executed by DCs are their ability to
recognize unique pathogen associated molecular patterns (PAMPs) via pattern
recognition receptors (PRRs) such as toll like receptors (TLRs), ability to uptake
antigens and secrete cytokines. Additionally, studies have shown the existence
of distinct DC subsets in vivo (Shortman and Naik, 2007). These include the
steady-state DCs and inflammatory DCs. Steady-state DCs are mostly lymphoid
organ resident. The inflammatory DCs, on the other hand, constitute a novel DC
population that are absent in the steady-state and appear only following an
inflammatory response. These DCs, characterized by copious production of TNFα and expression of inducible NO synthase (iNOS), are derived in vitro using
GM-CSF/IL4 (Xu et al., 2007).
Studies by Vorderstrasse and colleagues established DCs as a sensitive
target of TCDD, demonstrating a loss of splenic DCs following AhR activation
(Vorderstrasse and Kerkvliet, 2001). Additional studies have linked functional
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alterations of DCs to defective T cell responses and immune suppression
following AhR activation. For instance, studies conducted by Ruby et al., showed
that TCDD-treatment of BMDCs enhanced TNF-α-induced maturation, and
augmented CD95-mediated BMDC apoptosis (Ruby et al., 2005). Recently, AhR
activation by TCDD was also demonstrated to induce down regulation of RelB
mRNA levels in GM-CSF-derived BMDCs (Lee et al., 2007). DCs play a central
role in both innate and adaptive immunity, however the effects of AhR activation
on DCs remain poorly understood. Thus, the aim of this study was to
characterize the effects of AhR activation on the fate and function of
inflammatory DCs. We hypothesize that AhR activation alters the differentiation
of murine inflammatory DCs, an effect that may underlie the generation of TCDDinduced immune suppression. In this study, we explored the effects of AhR
activation on DC differentiation, antigen-uptake, TLR responsiveness and
production of Treg-inducing mediators. Mechanistically, we examined the role of
DREs in the generation of AhR-induced effects on DCs. The data presented in
this paper provides new information on the consequences associated with AhR
activation in DCs.
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MATERIALS AND METHOD
Animals: 6-8 week old C57Bl/6 (AhR+/+) mice were purchased from Jackson
Laboratory (Bar Harbor, ML). Breeding pairs of AhR knockout mice (AhR-/-) were
kindly provided by Dr. Paige Lawrence (URMC, Rochester, NY). AhRdbd/dbd and
AhRnls/nls mutant mice were generously provided by Dr. Chris Bradfield and Dr.
Ed Glover (University of Wisconsin-Madison) and subsequently maintained at
UM. Animal experiments were approved by the UM IACUC and adhered to the
current NIH guidelines for animal usage. Animals were provided rodent chow and
tap water ad libitum.
Chemicals: TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) in DMSO was obtained
from Cambridge Isotope laboratories Inc., (Woburn MA). 6-formylindolo[3,2b]carbazole (FICZ) and 2-(1H-Indol-3-ylcarbonyl)-4-thiazolecarboxylic acid (ITE)
were obtained from BIOMOL (Plymouth Meeting, PA) and Tocris (Ellisville,
Missouri), respectively. DMSO was used as a vehicle for all AhR ligands. Unless
specified, TCDD was used at a concentration of 10nM. Final concentration of the
solvent in culture was below 0.1% DMSO and did not induce cytotoxicity.
Generation of BMDCs: Bone marrow-derived dendritic cells were prepared
using methods as described by Inaba and coworkers (Inaba et al., 1992). Briefly,
bone marrow cells were flushed from the femurs of C57Bl/6 or AhR mutant mice
using complete RPMI (cRPMI) media. Bone marrow cells were centrifuged at low
speed and red blood cells were removed by gradient centrifugation using
lympholyte-M (Cedarlane; Hornby, Canada). Bone marrow cells were washed

102

twice and plated at a density of 1x106cells/ml in tissue culture flasks or 6 well
plates. Cells were cultured in media with 30ng/ml GM-CSF and Vehicle or TCDD
(10nM) for 3 days at 37° C and 5 % CO2. On days 3 and 5, non-adherent cells
were collected washed once and reseeded. Fresh media, GM-CSF (30ng/ml),
vehicle or TCDD (10nM) was added to the culture flask. Non-adherent cells were
harvested on day 7 and BMDCs were purified (≥ 85-90%) with CD11c-APC mAb
and anti-APC beads (Miltenyi Biotec, Auburn, CA) using MACS separation
columns as per the manufacturer’s instructions.
Immunophenotypic analysis of BMDCs: BMDCs were stained for FACS
analysis as previously described (Shepherd et al., 2001). Briefly, rat, hamster or
mouse IgG block was added to prepared leukocytes for 10 minutes on ice to
prevent non-specific binding. Cells were stained for 10 minutes on ice cells with
monoclonal antibodies (mAb) from BDPharmingen (San Diego, CA): CD11c
(HL3), MHCII (2G9), CD86 (GL1), CD45.2 (104), CD62L (MEL14), CD44 (IM7)
and Biolegend (San Diego, CA): CD25 (PC61). All mAbs used were optimallytitrated and isotype-matched mAbs were used as controls. Acquisition of 40,000300,000 events was performed using a FACS Aria flow cytometer. (BD
biosciences) and analyzed by BD FACS Diva software (Version 4.0).
Activation of BMDCs with TLR ligands and cytokine assays: Purified vehicle
or TCDD-treated BMDCs were cultured in 6 well plates at a density of 1x106 per
well and stimulated with LPS at 1 µg/ml (Sigma) or CpG at 0.5µM (Invivogen, SA,
USA) for 24 hrs. IL-6, TNF-α, IL-12p70 and IL-10 levels in the supernatants from
TLR ligand-stimulated BMDCs were measured by enzyme linked immunosorbent
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assay (ELISA). Samples were analyzed as per the manufacturer’s instructions
using cytokine-specific BD ELISA kits (BD Pharmingen)
NO measurement: NO levels in supernatants from TLR-activated BMDCs were
assessed using the Griess assay. The assay was conducted as per the
manufacturer’s instructions (Promega, Madison, USA).
Antigen uptake: To measure phagocytic potential, BMDCs were incubated with
acetylated LDL-FITC (Molecular probes, Oregon, USA) for 1.5 hours, FITC–
ovalbumin (Molecular probes, Oregon, USA) for 12 hours or latex beads-FITC
(Polysciences, Warrington, PA) for 6 hours. Antigen uptake was subsequently
assessed by flow cytometry.
T cell activation: To assess the ability of BMDCs to activate CD4+ T cell in an
Ag-specific fashion, the OT II adoptive transfer model was employed. Briefly,
CD45.2+ BMDCs were generated in the presence of GM-CSF and TCDD (10nM)
or vehicle. On day 7, BMDCs were purified and loaded with whole OVA. Vehicleor TCDD-treated, antigen-laden BMDCs (1x106/footpad) were transferred into
host CD45.1 mice that had previously received TCR transgenic OT II T cells
intravenously (2x106/mouse) one day prior. Lymph nodes were harvested on day
4 post-immunization and donor DCs and OT II T cells analyzed by flow
cytometry. Co-expression of CD45.2/CD11c or CD4+/Thy1.1 was used to track
donor DCs or OT II T cells, respectively. The activation status of donor OT II T
cells was assessed phenotypically using the markers CD44 and CD62L.
Quantitative real-time reverse transcription-polymerase chain reaction
(qRT-PCR): Total RNA was isolated using Trizol reagent and quantified by
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absorbance at 260nm. Single strand cDNA synthesis was carried using a RTPCR kit (SAbiosciences) and prepared as per the manufacturer’s instructions.
Specific primers for IDO1, IDO2, TGF-β1, TGF-β2, TGF-β3, latent transforming
growth factor beta binding protein 3 (Ltbp3), Aldehyde dehydrogenase family 1,
subfamily A2 (Aldh1a2), Thrombospondin 1 (Thbs1), Plasminogen activator
(Plat) and β-actin were obtained from SABiosciences. Quantitative detection of
mRNA expression was performed on a Light cycler Instrument (Biorad IQTM 5,
Multicolor

Real

Time

PCR

Detection

Systems)

using

SYBR

green

(SAbiosciences) according to the manufacturer’s instructions.
NF-kB activity: Purified BMDCs (1.5x106/well) were stimulated with LPS
(1µg/ml) or CpG (0.5µM/ml) for 30 minutes in 6-well plates. Cells were harvested
and nuclear protein extracts prepared using the Active Motif nuclear lysis kit
(Active Motif, Carlsbad, CA). The protein content of the nuclear extract was
measured using a BCA protein assay kit (Pierce, Rockford, IL). Nuclear protein
(2.5 µg/ml per well) was then added to the Active Motif TransAM NF (Motif,
Carlsbad, CA) and assayed according to the manufacturer’s specifications.
Statistical analysis: Student’s t test was used to compare means of vehicletreated groups to TCDD–exposed groups. Data sets with multiple comparisions
were evaluated by one-way analysis of variance (ANOVA) with Bonferroni’s post
test. For analysis, values of p ≤ 0.05 were considered significant.
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RESULTS
AhR activation alters BMDC growth and differentiation: We first examined
the effects of TCDD on the growth of BMDCs. Bone marrow cells were induced
to differentiate into DCs with GM-CSF in the presence of vehicle or TCDD
(10nM) for 7 days. On day 7 both adherent and non-adherent fractions were
harvested. TCDD increased the number of non-adherent cells by 50 percent, but
had no effect on the adherent cells obtained on day 7 when compared to vehicletreated controls (Table 3-1). Both vehicle- and TCDD-treated BMDCs were >95%
viable (data not shown). Non-adherent cells were immunophenotyped using the
murine DC marker, CD11c and costimulatory/differentiation markers MHC Class
II, CD86, CD11a, CD54 and CD25. TCDD increased the frequency of CD11c+
BMDCs but decreased the relative expression of this lineage marker when
compared to vehicle-treated controls. Additionally, TCDD increased MHC II,
CD86 and CD25 expression but decreased CD11a and CD54 expression on
BMDCs (Figure 3-1). TCDD altered BMDC differentiation at very low
concentrations. A concentration of 0.01nM TCDD upregulated the expression of
CD11c, MHC Class IIhigh and CD86high expression on BMDCs when compared to
vehicle-treated controls (Figure 3-2). In addition to TCDD, many natural (TCDDlike) ligands bind and activate the AhR. To examine the affects of non-TCDD
chemicals on BMDC differentiation, cells were treated with two natural AhR
ligands, FICZ and ITE. Similar to TCDD, FICZ and ITE decreased CD11c
expression and increased levels of MHC Class II and CD86 on the BMDCs
(Figure 3-3).
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Table 3-1: Effects of TCDD on the number of murine bone marrow dendritic
cells a

Number of cells (x106)

a

Vehicle

TCDD

Non-adherent

16.3 ± 1.2

24.0 ± 4.6*

Adherent cells

9.3 ± 0.7

7.1 ± 2.9

BMDCs were grown in presence of vehicle or TCDD. Cells were harvested on

day 7 and ennumerated as described in the materials and methods section.
Viability of the cells was ≥ 95% as determined by trypan blue staining Data
represent the mean ± SEM of 9 independent samples per treatment group.
*p<0.05 indicates significant differences between vehicle and TCDD-treated
groups.
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Figure 3-1

CD11c
MHC II
CD86
CD11a
CD54
CD25

Percentage
MFI
Percentage
MFI
Percentage
MFI
Percentage
MFI
Percenatage
MFI
Percentage
MFI

Vehicle
56.7 ± 0.4
7737 ± 160
38.7 ± 0.8
690.8 ± 8
15.7 ± 0.3*
1905 ± 56
81.2 ± 0.7
3304 ± 53
81.7 ± 0.4
797 ± 24
4.8 ± 0.2
1775 ± 8

TCDD
60.6 ± 0.3*
5138 ± 54*
60.4 ± 0.6*
1182 ± 24*
27.2 ± 0.3*
2278 ± 29*
53.6 ± 0.7*
2147 ± 20*
67.0 ± 0.5*
654 ± 7.2*
18.6 ± 0.4*
2204 ± 11*

Figure 3-1: TCDD alters the expression of differentiation markers on
BMDCs: Bone marrow cells were induced to differentiate into immature DCs with
GM-CSF in the presence of vehicle (represented by dotted line in the histograms)
or 10 nM TCDD (thick line as indicated in the histograms). Isotype staining is
shown in gray lines. Non-adherent cells were harvested on day 7 and stained
with CD11c, MHC Class II, CD86, CD54, CD11a and CD25 and their expression
determined on CD11c+ BMDCs by FACS analysis. Data shown represent nonadherent cells obtained from 4 separate flasks per treatment group and is
representative of 3 independent experiments. *p<0.05 indicates significant
differences between vehicle-and TCDD-treated groups.
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Figure 3-2
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Figure 3-2: Low concentrations of TCDD alter BMDC differentiation: Bone
marrow cells were generated in the presence of GM-CSF and vehicle or varying
TCDD concentrations (0.001nM-10nM). Non-adherent cells were harvested on
day 7 and stained for CD11c, MHC II and CD86. Expression of MHC II and CD86
was determined on the CD11c+-gated population. Data represent mean ± SEM of
6 samples at each concentration. *p< 0.05 indicates significant differences
between the vehicle- and TCDD-treated group.
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Figure 3-3
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Figure 3-3: Natural AhR agonists alter BMDC differentiation: Bone marrowderived dendritic cells were grown in presence of vehicle or the natural AhR
agonists, FICZ and ITE. Non-adherent cells were harvested on day 7 and stained
for CD11c, MHC II and CD86. Expression of MHC II and CD86 was determined
on CD11c+-gated population. *indicates significant differences between treated
and respective vehicle control groups. Data represent mean ± SEM of 4 samples
per treatment group for 2 independent experiments.
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Effects of TCDD on BMDC differentiation are AhR-dependent but are not
exclusively DRE-mediated: To define the role of the AhR in TCDD-induced
alterations in the differentiation of BMDCs, we analyzed BMDCs from AhR-/-,
AhRdbd/dbd and AhRnls/nls mice. TCDD did not affect CD11c, MHC II and CD86
expression on AhR-/- BMDCs when compared to vehicle-treated controls (Figure
3-4). AhRnls/nls and AhRdbd/dbd mice express a mutant AhR that binds ligand but
fails to translocate in the nucleus or bind DREs, respectively. BMDCs from
AhRdbd/dbd mutant mice displayed decreased CD11c and increased MHC II and
CD86 expression following TCDD treatment (Figure 3-4). On the other hand,
BMDCs from AhRnls/nls mice displayed decreased CD11c and CD86, and a slight
but significant increase in the expression of MHC II following TCDD treatment.
Effects of TCDD on TLR responsiveness and TLR ligand-induced
production of inflammatory mediators: To evaluate the effects of TCDD on
the innate responsiveness of BMDCs, cells were cultured with the TLR ligands,
LPS (TLR4 agonist) and CpG (TLR9 agonist).

Consistent with our previous

results, TCDD increased MHC class IIhigh expression on unstimulated BMDCs
when compared to the unstimulated vehicle controls (Figure 3-5). As expected,
LPS- and CpG-treatment increased MHC Class IIhigh frequency of BMDCs when
compared to the unstimulated controls. TCDD significantly increased the LPSand CpG-induced frequency of BMDCs expressing high levels of MHC Class IIhigh
compared to respective vehicle-treated controls. TLR4 and TLR9 mRNA
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Figure 3-4
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Figure 3-4. The effects of TCDD on BMDCs are AhR-dependent and partially
DRE-dependent: BMDCs from AhR+/+, AhRdbd/-, AhRdbd/dbd and AhRnls/nls were
treated with vehicle or TCDD. Non-adherent cells were harvested on day 7 and
stained for CD11c, MHC II and CD86. Expression of MHC II and CD86 was
determined on the CD11c gated population and analyzed by Facs aria. Data
represent mean ± SEM of non-adherent cells obtained from 3-4 flasks per
treatment goup. *p<0.05 indicates significant differences between respective
vehicle- and TCDD-treated groups.
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Figure 3-5
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Figure 3-5. Effects of TCDD on LPS- and CpG–induced MHC Class IIhigh
expression: BMDCs were grown in vehicle or TCDD and non-adherent cells
were harvested on day 7. BMDCs were purified and treated with LPS or CpG for
24 hours. Cells were harvested after 24 hours and MHC class II expression was
assessed. Data represent mean ± SEM of 9 samples per treatment group and is
representative of 3 independent experiments. *p<0.05 indicates significant
differences between the respective vehicle- and TCDD-treated groups. #p<0.05
indicates significant differences between TLR-stimulated and respective
untreated groups.
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expression was not affected by TCDD as measured by RT-PCR (data not
shown). Additionally, AhR activation by TCDD increased both LPS- and CpGinduced IL-6 and TNF-α production but decreased NO production by BMDCs
(Table 3-2). TCDD did not affect IL-10 production by the BMDCs when compared
to the vehicle-treated controls. Although TCDD did not alter the LPS-induced IL12p70 production, it decreased the CpG-induced IL-12p70 production by the
BMDCs when compared to vehicle-treated BMDCs.

TCDD decreases LPS- and CpG-induced p65 but not RelB activity: NF-kB
signaling in DCs is activated following TLR stimulation. Additionally, based on the
potential of ligand-activated AhR to physically interact with NF-kB and alter
immune function, we evaluated NF-kB signaling in BMDCs (Ruby et al., 2002;
Vogel et al., 2007a). TCDD decreased p65, but not RelB activity in unstimulated
BMDCs when compared to unstimulated vehicle controls. LPS- and CpGtreatment increased p65 but not RelB activity in BMDCs when compared to the
unstimulated controls. TCDD significantly decreased LPS-and CpG-induced p65
activity in BMDCs when compared to respective vehicle-treated controls. TCDD
generated a trend towards upregulation of LPS- and CpG-induced RelB levels in
BMDCs when compared to the respective vehicle-treated controls (Figure 3-6).

Antigen uptake by BMDCs is modulated by TCDD: Dendritic cells take up
antigens by phagocytosis and receptor-mediated endocytosis. To monitor the
effects of TCDD on antigen uptake, BMDCs were evaluated for uptake of both
soluble and particulate antigens. As determined by flow cytometry, TCDD
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Figure 3-6
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Figure 3-6. LPS-and CpG-induced p65 but not Rel B activity is reduced by
TCDD: Vehicle- or TCDD-treated BMDCs were stimulated with LPS (1 µg/ml) or
CpG (0.5µM) for 0.5 hours. Cells were harvested and nuclear proteins isolated.
p65 and RelB activity was measured using the TransAM activity ELISA. *
indicates significant differences between LPS- or CpG-stimulated groups
compared to respective vehicle-treated control groups. Data represent mean ±
SEM of 3 samples per treatment group.
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Table 3-2: Effects of TCDD on cytokine production by BMDCsa
TNF-α (pg/ml)
Media
LPS
CpG

Vehicle
BD
4286 ± 407
5154 ± 207

TCDD
BD
9565 ± 266*
8556 ± 399*
IL-6 (pg/ml)

Media
LPS
CpG

Vehicle
BD
21960 ± 2000
22660 ± 1135

TCDD
BD
33080 ± 3592*
30590 ± 3029*
IL-10 (pg/ml)

Media
LPS
CpG

Vehicle
BD
1310 ± 76
694± 64

TCDD
BD
1538 ± 282
719 ± 43
IL-12p70 (pg/ml)

Media
LPS
CpG

Vehicle
BD
268 ± 36
640 ± 28

TCDD
BD
271 ± 34
581 ± 20*
NO (µM)

Media
LPS
CpG

Vehicle
0.4 ± 0.1
20 ± 2.2
16.2 ± 1.5

TCDD
0.5 ± 0.1
4 ± 0.3*
3.2 ± 0.2*

a

BMDCs were stimulated with LPS or CpG as described in Materials and
Methods. Supernatants were collected and levels of TNF-α, IL-6, IL-10 and IL12p70 determined by ELISA. Levels of NO were determined using the Griess
reagent. Data represent mean ± SEM of 4-9 samples for TNF-α, IL-6, IL-10 and
NO and is representative of 2 independent experiments. Data represent mean ±
SEM of 12-15 samples pooled from 2 separate experiments for IL-12p70. * p ≤
0.05 indicates significant differences between LPS- and CpG–stimulated BMDCs
as compared to respective vehicle-treated controls. BD represents below
detection.
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decreased BMDC uptake of the soluble antigens, ovalbumin and acetylated-LDL,
by 25 and 10 percent, respectively (Figure 3-7). Conversely, TCDD increased the
uptake of the particulate antigen, latex beads, by 40 percent when compared to
the vehicle-treated controls.

AhR activation upregulates mRNA levels of suppressive T reg-inducing
mediators. Potent T reg-inducing mediators such as IDO1, IDO2, Thbs1 and
TGF-β3 have been implicated in the generation of immune suppression following
AhR activation (Lawrence et al., 2008; Marshall et al., 2008; Vogel et al., 2008).
In this context, we examined the effects of AhR activation on the generation of
suppressive mediators in BMDCs. TCDD-treated BMDCs upregulated IDO1,
IDO2 and TGF-β3 levels by 18-, 24- and 11-fold, respectively (Table 3-3). TCDD
had no effect on the expression of LTBP, Aldh, Thbs1 or Plat in the BMDCs.
Following LPS treatment, TCDD-BMDCs displayed increased levels of IDO1,
IDO2, TGF-β1, TGF-β2 and Thbs1 when compared to vehicle-treated BMDCs.

AhR-activated BMDCs do not inhibit antigen-specific T cell responses: We
tested the ability of AhR-activated BMDCs to generate antigen-specific T cell
activation using the modified OT II adoptive transfer model. Vehicle- or TCDDtreated donor BMDCs (CD45.2+) were pulsed in vitro with whole ova to load
these APCs with antigen. Ova-loaded DCs were then used to activate adoptively
transferred, ova-specific OT II/Thy1.1 CD4+ T cells that had been adoptively
transferred into CD45.1 host mice. Peripheral lymph nodes were harvested on
day 4 following BMDC immunizations. Donor DCs obtained from mice receiving
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Figure 3-7
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Figure 3-7. TCDD alters antigen uptake by BMDCs: Vehicle- or TCDD-treated
BMDCs were purified and evaluated for the ability to take up FITC-conjugated
whole ovalbumin (FITC–Ova), low-density lipoprotein (LDL-FITC) and latex
beads was assessed. Cells were exposed to FITC-conjugated ovalbumin

LDL-fitc for 1.5 hours and FITC-latex beads for 6 hours prior to
LDL uptake overnight,
harvesting. Data represent mean ± SEM of 9-12 samples per treatment group
for 2 independent experiments. * p≤ 0.05 indicates significant differences
between vehicle- and TCDD-treated samples.

Ova uptake
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Table 3-3: AhR activation alters expression of suppressive mediatorsa

Unactivated

a

LPS-activated

Fold change

p value

Fold change

P value

IDO1

18*

0.0001

22*

≤0.001

IDO2

24*

≤0.001

25*

≤0.001

TGFβ1

0.4

0.1

1.8*

0.02

TGFβ2

0.9

0.9

2.3*

0.008

TGFβ3

11*

0.001

0.01

0.4

Ltbp3

0.2

0.3

1.3*

0.001

Aldh1a2

0.8

0.6

0.6

0.09

Thbs1

0.4

0.07

1.9*

0.01

Plat

1.2

0.4

1.0

0.8

Gene expression in resting and LPS-activated BMDCs was evaluated by real-

time RT-PCR. The results are expressed as TCDD-induced fold change after
normalization with the housekeeping gene, β-actin. N = 3-4 per treatment group.
* p≤ 0.05 indicates significant differences between vehicle- and TCDD-treated
BMDCs.
.
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Figure 3-8
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Figure 3-8. Ability of TCDD-treated BMDCs to activate antigen-specific T
cells: CD4+ T cells from OT II Thy1.1 were adoptively transferred into congenic
CD45.1 host mice on day -1 relative to immunization. On day 0, whole ovaloaded BMDCs, that were either vehicle- or TCDD-treated were injected into
adoptively transferred mice. On day 4 post-immunization, popliteal lymph nodes
were harvested from host mice and analyzed by flow cytometry. Analysis was
based on the differences in the phenotypic expression of cell surface molecule
between donor DCs (CD45.2/CD11c) and donor T cells (CD4/Valpha2/Thy1.1)
from host mice (CD45.1/Thy1.2). Data represent mean ± SEM of 4-5 animals per
treatment group. * p ≤ 0.05 indicates significant differences between vehicle- and
TCDD–treated groups. Dashed line represents the status of donor T cells in the
brachial lymph nodes.
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TCDD-treated BMDCs, displayed reduced MHC Class II frequency when
compared to vehicle-treated BMDCs. Ova-specific OT II T cells from the popliteal
lymph nodes exhibited significant clonal expansion when compared to the OT-II
T cells from non-draining BLNs (Figure 3-8 + data not shown). Host mice,
immunized with TCDD-treated BMDCs displayed an increase in the number, but
not the frequency of OT II T cells. Additionally, no differences were observed in
the expression of the activation markers CD62L and CD44 on donor T cells from
mice receiving TCDD-treated BMDCs when compared to donor T cells from mice
receiving vehicle-treated BMDCs (Figure 3-8).
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DISCUSSION

Dendritic cells are professional antigen presenting cells that play an
important role in both the innate and adaptive arms of the immune systems. In
this study, we have characterized the consequences of AhR activation on the
innate and adaptive functions of BMDCs and examined the role of DRE-mediated
events in the generation of these effects. We demonstrate that AhR activation
alters BMDC differentiation and induces a regulatory phenotype, but surprisingly
without altering the ability of the DCs to initiate Ag-specific activation of naïve,
CD4+ T cells.

Dendritic

cells

exist

in

multiple,

functionally

distinct

stages

of

differentiation. Several investigators have linked TCDD-induced modulation of
DC differentiation to the generation of defective T cell responses (Vorderstrasse
and Kerkvliet, 2001; Lee et al., 2007). In our study, TCDD decreased expression
of CD11c but increased MHC II and CD86 levels on BMDCs. Engagement of B7
(CD86) molecules on a DC with CD28 or CTLA4 on the surface of the T cell can
activate or impair T cell responses, respectively (Krummel and Allison, 1995;
Lenschow et al., 1996). Successful T cell activation involves not only interactions
between the TCR and Ag-associated MHC II, but also costimulatory interactions
such as CD28 and CD86. In this context, studies have linked TCDD-induced
increases in CD86 expression on DCs with increased T cell activation in an MLR
response (Lee et al., 2007). However, AhR activation has also been shown to
induce CTLA4 expression on T cells which can bind to CD86 on a DC with high
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affinity and impair T cell responses (Funatake et al., 2005). Thus, in the context
of AhR activation, ligation of CD86 on DCs with CTLA4 on T cells could
alternatively contribute towards the generation of immune suppression.
Furthermore, consistent with previous studies documenting TCDD-induced
modulation of the adhesion molecules CD11a and CD54, TCDD decreased the
expression of both these molecules on BMDCs (Shepherd et al., 2001;
Vorderstrasse and Kerkvliet, 2001). The decreased expression of adhesion
molecules on DCs could contribute to defective T cell activation and subsequent
immune suppression. TCDD-induced immune suppression has also been linked
to increased CD25 expression on T cells (Funatake et al., 2005). More recently,
CD25 was identified as a phenotypic marker for regulatory DCs (DCregs)
(Driesen et al., 2008) (von Bergwelt-Baildon et al., 2006). TCDD increased CD25
expression on BMDCs, suggesting the induction of a regulatory phenotype in the
BMDCs. Taken together, TCDD-induced alteration of molecules involved in Agpresentation, costimulation and adhesion could result in defective T cell
activation

contributing

to

immune

suppression.

Recently,

ligand-specific

activation of the AhR has been shown to generate Tregs or Th17 cells (Quintana
et al., 2008). However, the effects of ligand-specific activation in inflammatory
DCs have not been previously described. Interestingly, the AhR ligands, FICZ
and ITE generated phenotypical alterations in BMDCs similar to TCDD,
demonstrating a lack of differential responsiveness of DCs to an array of AhR
ligands.

While the AhR is essential for TCDD-induced immunotoxicity, no
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information exists regarding the role of DREs in TCDD-induced alterations of
DCs. We investigated the role of the AhR and DREs in TCDD-induced alteration
in DC differentiation using BMDCs from AhR null, AhRnls/nls and AhRdbd/dbd mice.
While the AhR null mice, lacking functional AhR receptor, enabled us to
determine the role of the AhR in the generation of TCDD-induced alterations in
DCs, involvement of DRE-mediated events was assessed using the AhRnls/nls and
AhRdbd/dbd mice expressing a mutant AhR that binds ligand but fails to translocate
into the nucleus or bind DREs, respectively. Our results show that the effects of
AhR activation in BMDCs are strictly AhR-dependent but not exclusively DREmediated. TCDD-treated BMDCs from AhRdbd/dbd mice displayed increased MHC
II and CD86 expression when compared to vehicle-treated AhRdbd/dbd BMDCs.
However, TCDD-induced increases in MHC II and CD86 expression in AhR dbd/dbd
BMDCs did not reach similar levels to those observed in TCDD-treated BMDCs
from AhRdbd/- control mice. This suggested that a non-DRE mediated mechanism
was contributing to the TCDD-induced differentiation of the DCs. Of the several
non-DRE mediated mechanisms implicated in TCDD immunotoxicity, interactions
of the activated AhR with NF-kB signaling components can induce defects in
DCs following TCDD exposure (Ruby et al., 2002; Vogel and Matsumura, 2008).
Thus, one possible explanation for the partial effects of TCDD on BMDC
differentiation as observed in DCs from AhRdbd/dbd and AhRnls/nls mice could be
due to altered NF-kB signaling.

A primary function of DCs is the recognition of PAMPs via PRRs such as
TLRs. Based on the observed TCDD-induced modulation of DC differentiation,
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we assessed whether TCDD-exposed BMDCs were responsive to PAMPs via
TLR activation. TCDD increased BMDC responsiveness to TLR stimulation via
TLR4 and TLR9 without affecting the basal mRNA levels of these receptors.
Following activation DCs secrete cytokines that orchestrate developing immune
responses. In our study, TCDD increased LPS- and CpG-induced IL-6 and TNFα production by BMDCs but decreased their production of nitric oxide. Multiple
possibilities could account for these observed effects. NF-kB independent
transcription factor, LPS-Induced TNF-α Factor (LITAF), is a transcription factor
that has been implicated in the LPS-induced expression of TNF-α and other
inflammatory cytokines (Sun et al., 2004; Tang et al., 2005). LITAF contains 7
DRE sequences and upregulation of LITAF in DCs could underlie our observed
TCDD-induced increases in LPS-induced proinflammatory cytokine secretion
(Sun et al., 2004). Recent studies have, however, documented the ability of
activated AhR to negatively regulate inflammatory responses in human
monocyte-derived DCs and murine macrophages (Lawrence et al., 2008; Kimura
et al., 2009). Discrepancies in these results could be attributed to differences in
the AhR agonists used in the respective studies (VAGF347 versus TCDD) or in
the cells that were examined (human monocyte DCs versus murine DCs or
macrophages). In addition, activation of inflammatory DCs by LPS or CpG
usually induces upregulation of nitric oxide synthase (NOS) and subsequently
increased NO production. AhR activation by TCDD has been shown to increase
pulmonary inducible NO synthase (iNOS) levels contributing to enhanced IFN-γ
production in the lungs (Neff-LaFord et al., 2007). Contrary to these reports, in
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our study TCDD decreased NO production by both unstimulated and TLRactivated BMDCs. Additonal investigation is warranted to further understand the
effect of TCDD on NO production by BMDCs.

A previous study examining the effects of TCDD on BMDCs reported
decreased mRNA levels of IL-10 but not IL-12 following LPS-stimulation (Lee et
al., 2007). Contrary to this study, our data indicates that TCDD does not alter the
production of IL-10 and decreases CpG-induced IL-12 production by BMDCs.
Different DC preparations (unpurified versus purified DCs) used in these two
studies could account for the observed differences. Under in vivo conditions,
inflammatory DCs function to limit infection by their secretion of inflammatory
cytokines. Induction of inflammation is a hallmark feature of TCDD-induced
immunotoxicity and our results suggest a role for DCs in TCDD-induced
inflammatory

responses.

However,

how

TCDD-induced

alterations

of

inflammatory DCs impacts the development of acute inflammation remains to be
determined.

NF-kB is a major signaling pathway involved in the differentiation of DCs
and their responsiveness to TLR stimulation. Furthermore, several studies have
linked physical interactions of activated AhR with NF-kB p65 and RelB, in the
generation of TCDD-induced cellular dysfunction and immune suppression (Ruby
et al., 2002; Camacho et al., 2005; Vogel et al., 2007a; Vogel et al., 2007b; Vogel
and Matsumura, 2008). Because TCDD alters the differentiation of DCs and their
responsiveness to TLRs, we investigated the effects of AhR activation on NF-kB
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signaling in inflammatory BMDCs. TCDD suppressed basal p65 activity in
unstimulated BMDCs as well as BMDCs activated by LPS and CpG.
Furthermore, a trend towards increased RelB activity was also observed in
TCDD-treated BMDCs. Binding of RelB/AhR to specific response elements
(RelB/AhRE) in certain target genes has been linked to the regulation of
cytokines and chemokines such as IL-8 and BLC following TCDD exposure
(Vogel et al., 2005; Vogel et al., 2007b; Vogel and Matsumura, 2008). It would be
of interest to determine if the enhanced production of IL-6 and TNF-α by TCDDtreated BMDCs is also regulated by increased interactions between activated
AhR and RelB. Overall, our data suggest that TCDD-induced modulation of DC
differentiation and their responsiveness to TLR stimulation may be mediated via
altered NF-kB signaling.

Dendritic cells capture antigens via distinct mechanisms. While soluble
antigen uptake primarily involves macropinocytic or receptor-mediated endocytic
events, particulate antigens are internalized primarily via phagocytosis
(Banchereau et al., 2000). TCDD decreased the uptake of the soluble antigens
ovalbumin and LDL but increased phagocytosis of latex beads by inflammatory
DCs. These results suggest that TCDD differentially impacts mechanisms of
antigen uptake. Studies have shown macrophage mannose receptor and
scavenger receptor A to mediate the endocytosis of ova and acetylated LDL,
respectively (Pearson et al., 1993; Becker et al., 2006; Burgdorf et al., 2007).
Therefore, based on our results, we hypothesize that decreased expression of
these receptors in BMDCs following exposure to TCDD leads to decreased
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uptake of soluble antigens. Conversely, TCDD increased the uptake of latex
beads by BMDCs. So far, only one study has described effects of TCDD on the
uptake of latex beads. In this in vivo study, uptake of latex beads by splenic DCs
was unaffected following TCDD exposure (Vorderstrasse et al., 2003). The
observed discrepancy in our results could be attributed to distinct antigen uptake
mechanisms in the two functionally distinct DC populations (steady-state versus
inflammatory), which could be differentially affected by TCDD.

Because our data demonstrated that TCDD altered antigen uptake, we
assessed the effects of TCDD on the T cell stimulatory capacity of inflammatory
BMDCs. Surprisingly, TCDD-treated BMDCs generated normal antigen-specific T
cell responses in vivo. These results were unexpected, as TCDD not only
induced a regulatory phenotype in BMDCs, but also increased their expression of
several regulatory mediators including IDO1, IDO2 and TGF-β3. Several
possibilities could account for the lack of T cell suppression by TCDD-treated
BMDCs. Though our results demonstrated that TCDD alters antigen uptake of
ovalbumin by BMDCs, it is possible that the observed decreases in antigen
uptake do not reach a physiological threshold below which T cell activation is
affected. Additionally, TCDD may increase the expression, but not the function or
activity of the suppressive mediators IDO1, IDO2 and TGF-β3. In this case, we
would not expect TCDD-treated BMDCs to contribute to the suppression of T cell
activation. Recent studies have linked AhR activation in DCs with suppression of
T cell responses (Hauben et al., 2008). In these studies, AhR-activated DCs
suppressed T cell responses only following LPS activation. Immature BMDCs did
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not alter T cell responses. Thus, we also evaluated the expression of the
suppressive mediators in BMDCs following LPS maturation. TCDD-treated
BMDCs stimulated with LPS displayed increased expression of IDO1, IDO2,
TGF-β1, TGF-β2 and Thbs1.

However, future experiments are needed to

determine whether TCDD-treated BMDCs stimulated with LPS can affect
antigen-specific T cell responses.

Collectively, we show that AhR activation alters inflammatory DC
differentiation, generating DCs that are hyperresponsive to TLR stimulation and
exhibit a regulatory phenotype in vitro. Surprisingly, these BMDCs fail to alter
antigen-specific T cell activation. However, further studies are needed to
examine the potential for AhR-activated DCs to contribute to the generation of
regulatory T cells and the suppression of T cell-mediated immune responses.
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ABSTRACT
Although Aryl hydrocarbon receptor (AhR) activation by its prototypical
ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces regulatory T cell
(Tregs), molecular mechanisms underlying immunosuppression are not well
understood. Dendritic cells (DCs) are key antigen presenting cells governing T
cell activation and differentiation. DCs are sensitive to TCDD and AhR activation
induces a regulatory phenotype in DCs. We hypothesize that AhR-activated
dendritic cells (DCs) induce the generation of adaptive Tregs ultimately
contributing to immune suppression. To test this hypothesis, purified bone
marrow-derived DCs (BMDCs), generated in the presence of vehicle or TCDD
were assessed for induction of adaptive Tregs in vitro. Additionally, suppression
of T cell activation in vivo by LPS-stimulated, vehicle- and TCDD-treated BMDCs
was assessed. TCDD-treated BMDCs did not induce the generation of adaptive
T regs in vitro or suppress T cell activation in vivo. These results suggest that
AhR-activated regulatory DCs do not induce the generation of adaptive Tregs
and that AhR-induced Treg development may be a direct effect of AhR activation
on T cells. Alternatively, AhR-activated DCs may contribute to the expansion of
natural Tregs, a possibility that remains to be tested.

Keywords: Aryl hydrocarbon receptor (AhR); dendritic cells (DCs); 2,3,7,8tetrachlorodibenzo-p-dioxin (TCDD); Indole amine-2,3-dioxygenase (IDO) ; FICZ,
6-formylindolo[3,2-b]carbazole.
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INTRODUCTION
TCDD

is

an

environmental

pollutant

that

induces

profound

immunosuppression via activation of the Aryl hydrocarbon receptor (AhR)(Ema et
al., 1994b; Okey et al., 1994). Following ligand binding, the AhR translocates into
the nucleus, where in conjunction with its dimeric partner the Aryl hydrocarbon
receptor nuclear translocater (ARNT) it binds to the dioxin response elements
(DREs) in target genes. Several studies have documented TCDD exposure to
decrease CD4+ T cell function and induce the generation of regulatory T cells
(Tregs), which function to maintain tolerance (Kerkvliet et al., 2002; Quintana et
al., 2008). Two distinct types of regulatory T cells have been described: natural
Tregs that arise in the thymus, and inducible/adaptive Tregs, that form from
CD4+CD25-Foxp3- precursors in the periphery (Shevach, 2006; Sakaguchi et al.,
2008; Yamazaki and Steinman, 2009).
Several investigators have described the induction of Tregs following
TCDD exposure (Funatake et al., 2005; Marshall et al., 2008; Quintana et al.,
2008). Additionally, the increase in Tregs following AhR activation has been
associated with an increased production of Treg mediators including TGF-β3 and
indoleamine-2, 3-dioxygenases (IDO) (Marshall et al., 2008; Vogel et al., 2008).
Despite these reports, little is known about the mechanisms underlying
generation of Tregs following TCDD exposure.
Dendritic cells (DCs) are central antigen presenting cells that express the
AhR constitutively. We have previously demonstrated that TCDD induces a
regulatory phenotype in BMDCs that is characterized by an increased expression
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of IDO1, IDO2 and TGF-β3. Thus, the induction of regulatory DCs following AhR
activation may underlie generation of Tregs and subsequent immune
suppression. We hypothesize that AhR-activated DCs promote the generation of
adaptive Tregs. In this study, we evaluated the role of DREs in the TCDDinduced expression of suppressive regulatory mediators in BMDCs and
examined the ability of TCDD-exposed APCs to induce Tregs.

139

MATERIALS AND METHODS
Animals: 6-8 week old C57Bl/6 (AhR+/+) mice were purchased from Jackson
Laboratory (Bar Harbor, ML). Breeding pairs of AhR knockout mice (AhR-/-) were
kindly provided by Dr. Paige Lawrence (URMC, Rochester, NY). AhRnls/nls and
AhRdbd/dbd mice were initially acquired from Dr. Chris Bradfield and Dr. Ed Glover
(University of Wisconsin-Madison) and subsequently bred and maintained at UM.
AhRnls/nls and AhRdbd/dbd mice bear a mutant AhR that binds the ligand, but is
defective in nuclear translocation and binding the DREs, respectively. Animal
experiments were approved by the UM IACUC and adhered to the current NIH
guidelines for animal usage. Animals were provided rodent chow and tap water
ad libitum.
Chemicals: TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) in DMSO was obtained
from Cambridge Isotope laboratories Inc., (Woburn MA). 6-formylindolo[3,2b]carbazole (FICZ) was obtained from BIOMOL. DMSO was used as a vehicle
for all AhR ligands. TCDD and FICZ were used at a concentration of 10nM. Final
concentration of the vehicle in culture was below 0.1% DMSO and did not induce
cytotoxicity. rIL-2 was obtained from R and D systems (Minneapolis, MN) and
TGF-β1 was obtained from ebiosciences (San Diego, CA).
Generation of BMDCs: Bone marrow-derived dendritic cells were prepared
using methods from Inaba et al. (1992). Briefly, the bone marrow cells were
flushed using complete RPMI (cRPMI) media from the bone shafts of C57Bl/6 or
AhR mutant mice. Bone marrow cells were centrifuged at low speed and red
blood cells were removed by gradient centrifugation using lympholyte-M
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(Cedarlane, Hornby, Canada). Bone marrow cells were washed twice and plated
at a density of 1x106cells/ml in tissue culture flasks. Cells were cultured in media
with GM-CSF (30ng/ml) and Vehicle or TCDD (10nM) for 7 days at 37° C and 5
% CO2. On days 3 and 5, non-adherent cells were collected washed once and
reseeded back into culture flask. Fresh media, GM-CSF (30ng/ml), vehicle or
TCDD (10nM) was added to the culture flask and ultimately non-adherent cells
harvested on day 7. BMDCs were purified (≥85-90%) using CD11c-APC antibody
and anti-APC beads (Miltenyi Biotec, Auburn, CA) or CD11c beads (Miltenyi
Biotec, Auburn, CA). Following purification, BMDCs were loaded with ovapeptide (50µg/ml cPRMI) and harvested after 2 hours. For some experiments
BMDCs were simultaneously treated with LPS (1µg/ml) and ova-peptide
(50µg/ml cPRMI) and harvested after 12 hours.
T cell purification: Splenocytes were isolated from OT II mice and prepared as
previously described (Shepherd et al., 2001). CD4+ cells were isolated using the
CD4 T cell isolation kit as per the manufacturer’s instructions (Miltenyi, CA). Cell
purity as determined by flow cytometry was ≥ 90%. Purified CD4+ cells were
labeled with anti-CD25 PE and MACS anti-PE beads and positively selected
using LS columns (MACS separation columns). The purity of CD4+CD25+ and
CD4+CD25- cells obtained was 75% and 85%, respectively.
Immunophenotypic analysis of BMDCs and T cells: Harvested immune cells
were stained for FACS analysis as previously described (Shepherd et al., 2001).
Briefly, rat, hamster or mouse IgG block was added to prepared cells for 10
minutes on ice to prevent non-specific binding. Cells were stained for 10 minutes

141

on ice cells with monoclonal antibodies (mAb) from BDPharmingen (San Diego,
CA): CD11c (HL3), MHCII (2G9), CD86 (GL1), CD62L (MEL14), CD44 (IM7) and
Biolegend (San Diego, CA): CD25 (PC61). All mAbs used were optimally titrated
and appropriately-labeled, isotype-matched mAbs were used as controls.
Acquisition of 40,000-50,000 events was performed using a Facs Aria flow
cytometer. (BD biosciences) and analyzed by BD FACS Diva software (Version
4.0).
Quantitative real-time reverse transcription-polymerase chain reaction
(qRT-PCR): Total RNA was isolated using Trizol reagent and quantified by
absorbance at 260nm. Single strand cDNA synthesis was performed using a RTPCR kit (SAbiosciences) and prepared as per the manufacturer’s instructions.
Specific primers for IDO1, IDO2, TGFβ-1, TGF-β2, TGF-β3, latent transforming
growth factor beta binding protein 3 (Ltbp3), Aldehyde dehydrogenase family 1,
subfamily A2 (Aldh1a2), Thrombospondin 1 (Thbs1), and β-actin were obtained
from SABiosciences. Quantitative detection of mRNA expression was performed
on a Light cycler Instrument (Biorad IQTM 5, Multicolor Real Time PCR Detection
Systems) using SYBR green (SAbiosciences) according to the manufacturer’s
instructions.
In Vitro Suppression Assay: Purified CD4+CD25+ cells were suspended at a
final concentration of 1x106 cells/ml in complete RPMI (cRPMI) media and
cultured in 6 well plates coated with plate bound anti-CD3 (2µg/ml) and
supplemented with rIL-2 (250U/ml) and TGF-β1 (2ng/ml). CD4+CD25- cells were
co-cultured with DCs in a suppression assay as described below. Purified,
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vehicle- or TCDD-treated BMDCs (1x106/ml) were loaded with ova-peptide
(OVA323-339) for 2 hrs in 6 well plates. Ova-peptide loaded DCs were
subsequently co-cultured with purified, CD4+CD25- OT II T cells at a DC to T cell
ratio of 1:4, at a final concentration of 1 x106/ml in 6 well plates. After 4 days in
culture, cells were harvested and stained for CD4, CD25 and Foxp3.
T cell activation: To assess the ability of LPS-activated BMDCs to activate
CD4+ T cell in an antigen-specific fashion, the OT II adoptive transfer model was
employed.

Briefly, CD45.2+ inflammatory BMDCs were generated in the

presence of vehicle or TCDD (10nM), purified and subsequently treated with LPS
(1µg/ml) and ova-peptide (50µg/ml) for 12 hrs. LPS-activated, ova-peptide
loaded BMDCs were injected (1x106/footpad) into host CD45.1+ congenic mice
that had previously received one day prior OT II T cells (2x106/mouse)
intravenously. Popliteal Lymph nodes were harvested on day 5 postimmunization, processed and donor DCs and OT II T cells identified by flow
cytometry. The expression of CD45.2+/CD11c+ or CD4+/Thy1.1+ cells was
employed to track donor DCs or OT II T cells, respectively. The activation status
of antigen-specific donor OT II T cells was assessed immunophenotypically using
the markers CD44 and CD62L.
Statistical analysis: Student’s t test was used to compare the means of vehicletreated groups to TCDD–exposed groups. For analysis, values of p ≤ 0.05 were
considered significant.
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RESULTS
TCDD-induced expression of IDO1 and IDO2 and TGFβ -3 in BMDCs is AhRdependent. We have previously shown that AhR activation by TCDD increases
the expression of IDO1, IDO2 and TGFβ-3 in inflammatory BMDCs. To
determine the role of the AhR in the induction of these mediators, we assessed
their expression in vehicle- or TCDD-treated BMDCs from AhR null and wildtype
mice. As shown in table 4-1, TCDD increased the expression of IDO1, IDO2 and
TGFβ3 in AhR wild type mice. On, the other hand, TCDD did not alter gene
expression in AhR KO BMDCs, suggesting that the induction of these mediators
following TCDD exposure was AhR-dependent (Table 4-1).
TCDD-induced expression of IDO1 and IDO2 but not TGF-β 3 in BMDCs is
DRE-dependent: To determine the role of the DRE-mediated events in the
induction of these mediators, we assessed their expression in BMDCs from
AhRdbd/dbd and AhRnls/nls mice. TCDD-treated BMDCs from AhRdbd/dbd increased
TGFβ-2 and TGFβ-3 mRNA expression by 1.6- and 2.9- fold, respectively (Table
4-2A). Additionally, TCDD increased the expression of TGF-β2, TGF-β3, Aldh1a
and Thbs in BMDCs from AhRnls/nls mice by 2.3-, 6.2-, 2.6- and 1.6-fold,
respectively (Table 4-2B).
FICZ, a natural AhR ligand, increases expression of Treg-inducing
mediators. More recently, tryptophan metabolites such as 6-formylindolo[3,2b]carbazole (FICZ) have been described as high-affinity natural AhR ligands
(Oberg et al., 2005; Henry et al., 2006). Our previous studies have demonstrated
that FICZ generates phenotypical alterations in inflammatory BMDCs, similar to
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Table 4-1: The AhR is required for TCDD-induced changes in the
expression of regulatory mediatorsa

TCDD-induced fold
change in AhR wildtype

TCDD-induced fold
p value

BMDCs

a

change in AhR-/-

p value

BMDCs

IDO1

18*

0.0001

0.6

0.4

IDO2

24*

≤0.001

1.3

0.2

TGFβ1

0.4

0.1

0.9

0.8

TGFβ2

0.9

0.9

0.9

0.8

TGFβ3

11*

0.001

0.5

0.1

Ltbp3

0.2

0.3

1.0

0.9

Aldh1a2

0.8

0.6

1.0

0.6

Thbs1

0.4

0.07

1.1

0.1

Gene expression was evaluated in AhR wild-type and AhR null BMDCs by qRT-

PCR. The results are expressed as TCDD-induced fold change when compared
to the vehicle-treated controls after normalization with the housekeeping gene, β
actin. The experiment was conducted with N = 3 per treatment group. *p ≤ 0.05
was considered significant for all analysis conducted between vehicle-treated
and TCDD-treated BMDCs.
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Table 4-2: Role of DRE-mediated events in the TCDD-induced gene
expression of regulatory mediators in BMDCs

A.

IDO 1
IDO 2
TGFβ1
TGFβ2
TGFβ3
Ltbp3
Aldh1a
Thbs1

TCDD-induced
fold change in
AhRdbd/- BMDCs
4.5*
7.6*
0.8
1.7
15*
-1.8*
1.4
0.8

p value

TCDD-induced
fold change in
AhRdbd/- BMDCs
8.5*
1.9*
0.8
1.7
8.8*
0.7
1.5*
1.2

p value

0.003
0.0004
0.3
0.2
≤0.001
0.02
0.2
0.5

TCDD-induced
fold change in
AhRdbd/dbd BMDCs
-1.5*
0.8
0.8
1.6*
2.9*
-2.1*
1.5
0.1

p value

TCDD-induced
fold change in
AhRnls/nls BMDCs
2.5
1.2
0.8
2.3*
6.2*
0.9
2.6*
1.6*

p value

0.03
0.6
0.2
0.04
0.008
0.005
0.07
0.1

B.

IDO 1
IDO 2
TGFβ1
TGFβ2
TGFβ3
Ltbp3
Aldh1a
Thbs1

0.005
0.04
0.2
0.2
0.009
0.14
0.004
0.33

0.1
0.4
0.2
0.004
0.001
0.7
0.001
0.01

a

Gene expression was evaluated from A) AhRdbd/- and AhRdbd/dbd B) AhRdbd/-and
AhRnls/nls BMDCs by qRT-PCR. The results are expressed as TCDD-induced fold
change after normalization with the housekeeping gene, β actin. The experiment
was conducted with N = 3 per treatment group. *p ≤ 0.05 was considered
significant for all analysis conducted between vehicle-treated and TCDD-treated
BMDCs.
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TCDD. These results suggest that unlike T cells AhR activation in DCs by
exogenous or natural AhR ligands is not ligand-specific. To further assess the
effects AhR activation by a natural ligand, we examined the induction of
suppressive mediators in BMDCs following FICZ treatment. As shown in table 43, BMDCs displayed an increase in expression of IDO1, IDO2, TGF-β2, TGF-β3
and Aldh1a following exposure to FICZ when compared to vehicle-treated cells
(Table 4-3).
Effects of TCDD-treated BMDCs on the generation of CD4+CD25+ Foxp3+T
cells in vitro: Regulatory T cells can be segregated into two distinct lineages
referred to as natural T regs and adaptive Tregs. Several studies have shown
have linked TCDD-induced immune suppression with the induction of Tregs.
TCDD induced not only a regulatory phenotype in BMDCs, but also increased
their expression of several suppressive mediators. We therefore, assessed the
ability of TCDD-treated BMDCs to induce the conversion of CD4+CD25- CD4+ T
cells into CD4+CD25+ Foxp3+ T cells. Compared to vehicle-treated BMDCs,
TCDD-treated BMDCs decreased the frequency and the number of CD4+CD25+
Foxp3+ T cells (Figure 4-1).
LPS-activated, TCDD-treated BMDCs do not suppress antigen-specific T
cell activation in vivo: We previously demonstrated that TCDD-treated BMDCs,
displaying high expression of suppressive mediators fail to suppress antigenspecific T cell activation in an OT II adoptive transfer model. Recent studies have
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Table 4-3: AhR activation by natural ligand FICZ alters gene expressiona

FICZ-induced fold change in AhR
wildtype BMDCs
7.4*
14*
0.5
2.2*
9.3*
0.8
1.2*
0.7

IDO 1
IDO 2
TGFβ1
TGFβ2
TGFβ3
Ltbp3
Aldh1a2
Thbs
a

p value
0.003
0.001
0.11
0.006
0.001
0.12
0.02
0.5

Gene expression was evaluated from BMDCs by qRT-PCR. The results are

expressed

as

FICZ-induced

fold

change

after

normalization

with

the

housekeeping gene, β actin. The experiment was conducted with N = 3 per
treatment group. * p≤ 0.05 indicates significant differences between vehicletreated and FICZ-treated BMDCs.
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linked AhR activation in DCs with suppression of T cell responses (Hauben et al.,
2008). These studies demonstrated AhR-activated DCs to suppress T cell
responses only following LPS stimulation. Immature BMDCs did not alter T cell
responses. Thus, we also evaluated the expression of the suppressive mediators
in BMDCs following 8 hours LPS maturation. TCDD-treated BMDCs stimulated
with LPS displayed increased levels of IDO1, IDO2 and TGF-β3 as compared to
LPS-stimulated, vehicle-treated BMDCs (Table 4-4). We next tested the ability of
LPS-activated, TCDD-treated BMDCs to suppress antigen-specific T cell
activation in vivo using a modified OT II adoptive transfer model. LPS-activated,
vehicle- or TCDD-treated BMDCs were pulsed in vitro with ova-peptide to
generate ova-loaded DCs capable of activating adoptively transferred, ovaspecific OT II CD4+ T cells in vivo. Peripheral lymph nodes were harvested on
day 5 following BMDC immunizations. No effects on the number, frequency or
activation profile of donor DCs were observed in mice receiving LPS-activated,
TCDD-treated BMDCs as compared to LPS-activated, vehicle-treated BMDCs
(Figure 4-2). Ova-specific OT II T cells from the popliteal lymph nodes exhibited
significant clonal expansion when compared to the OT II T cells from nondraining BLNs, indicating antigen-specific activation. However, no differences in
the frequency, number or the activation profile of the OT II T cells were detected
in mice immunized with antigen-laden, LPS-stimulated donor BMDCs treated
with vehicle or TCDD.

149

Table 4-4
Effects of 8 hours LPS stimulation on TCDD-induced regulatory gene
expression in BMDCs.

IDO 1
IDO 2
TGFβ1
TGFβ2
TGFβ3
Aldh1a
Thbs1

a

TCDD-induced fold change following 8
hrs LPS stimulation
15*
14*
1.7
-2.3
5.7*
-2.6*
1.0

p value
0.0004
0.002
0.05
0.01
0.003
0.01
0.5

Gene expression was evaluated by qRT-PCR in vehicle- and TCDD-treated

BMDCs stimulated with LPS for 8 hours. The results are expressed as TCDDinduced fold change when compared to vehicle-treated controls after
normalization to the housekeeping gene, β actin. The experiment was conducted
with N = 2 per treatment group. *p ≤ 0.05 was considered significant for all
analysis conducted between vehicle-treated and TCDD-treated BMDCs.

150

Figure 4-1

1.0

2.5

0.8

2.0

0.6

1.5

*

0.4
0.2
0.0

1.0

*

0.5

Vehicle

TCDD

0.0

Vehicle

TCDD

Figure 4-1. Effects of TCDD-treated BMDCs on the generation of Foxp3+
Tregs from conventional CD4+ T cells.
Ova-peptide loaded, vehicle or TCDD BMDCs were co-cultured with purified
CD4+CD25- OT II T cells in 6 well plates at a 1:4 DC to T cell ratio at a final
concentration of 1 x106 total cells per well. After 4 days in culture, cells were
harvested and the frequency and number of CD4+CD25+Foxp3+ T cells
determined. Data represent mean ± SEM of n=3 per treatment group. * p ≤ 0.05
indicates significant differences between vehicle- and TCDD–treated groups
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Figure 4-2
0.25

10.0

0.20
7.5

0.15
5.0

0.10

2.5

0.05
0.00

Vehicle

0.0

TCDD

3.5

Vehicle

TCDD

2.0

3.0
1.5

2.5
2.0

1.0

1.5
1.0

0.5

0.5
0.0

Vehicle

DC activation markers
T cell activation markers

0.0

TCDD

% CD86
% MHC II
CD62 L MFI
CD44 MFI

Vehicle

Vehicle
35 ± 3.6
62 ± 3.7
284 ± 18
2150± 119

TCDD

TCDD
38 ± 10.3
55 ± 3.2
302 ± 36
1884 ± 87.4

Figure 4-2. Effects of LPS-matured, TCDD-treated, ova-peptide loaded
BMDCs on antigen-specific T cell proliferation in vivo: CD4+ T cells from OT
II Thy1.1 mice were adoptively transferred into CD45.1 host mice, 24 hours
before immunization with LPS-stimulated, ova-peptide loaded BMDCs, that were
either vehicle- or TCDD-treated. On day 5 post-immunization, popliteal lymph
nodes were harvested and the donor DCs and donor T cells analyzed by flow
cytometry as described in materials and methods. Data represent mean ± SEM
of 4-5 animals per treatment group. * p ≤ 0.05 indicates significant differences
between vehicle- and TCDD–treated groups.
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DISCUSSION
We have previously reported that AhR activation by TCDD induces a
regulatory phenotype in DCs characterized by an increased expression of IDO1,
IDO2 and TGF-β3 mRNA levels. However, these studies did not address the
effects of regulatory DCs on T cell differentiation, specifically the generation of
regulatory T cells. In this study, we have assessed the role of the AhR and DREmediated events in the induction of regulatory mediators in DCs and evaluated
the potential of AhR-activated BMDCs to induce adaptive Tregs.
TCDD-induced toxicity is associated with activation of both DRE and non–
DRE-mediated AhR signaling pathways. We have previously demonstrated that
TCDD modulates BMDC differentiation via mechanisms that are strictly AhRdependent but not exclusively DRE-mediated (unpublished data). Consistent with
these studies, TCDD-induced expression of regulatory mediators in BMDCs was
found to be AhR-dependent. The potential involvement of DREs in the
expression of these mediators was further assessed using BMDCs from
AhRdbd/dbd and AhRnls/nls mice harboring a mutant AhR that binds ligand but fails
to translocate to the nucleus or bind to DREs, respectively. TCDD did not
significantly increases the expression of IDO1 or IDO2 in AhRdbd/dbd or AhRnls/nls
BMDCs, suggesting that their induction by TCDD required binding of the
activated AhR to the DREs. Conversely, TCDD increased expression of both
TGF-β2 and TGF-β3 in AhRdbd/dbd and AhRnls/nls BMDCs. Interestingly, increases
in TGF-β3 expression by TCDD in both AhRdbd/dbd and AhRnls/nls BMDCs were
less compared to TCDD-induced increases in AhRdbd/- control BMDCs suggesting
that TCDD-induced expression of TGF-β2 and TGF-β3 expression in
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inflammatory BMDCs may be partially regulated by DRE-mediated events. Other
genes that were slightly but significantly upregulated in AhRnls/nls BMDCs
following TCDD treatment included Thbs1 and Aldh1a. Aldh1a, an enzyme
involved in the production of retinoic acid is implicated in the production of Tregs
(Elias et al., 2008). A slight but significant increase in Aldh1a expression in
AhRnls/nls BMDCs following TCDD treatment suggests the involvement of
cytoplasmic, non-DRE mediated signaling events in the induction of regulatory
mediators following AhR activation.
Recently studies have identified natural ligands for the AhR such as the
tryptophan photoproduct, FICZ. Initial studies demonstrated that FICZ, a high
affinity AhR agonist, can induce Th17 differentiation and inhibit Treg (Quintana et
al., 2008). In contrast, Kimura et al., reported Treg induction by TGF-β that was
enhanced when the AhR was activated by either TCDD or FICZ (Kimura et al.,
2008). FICZ has been shown to increase the expression of CD86 on human
U937 monocyte-derived DCs (Veldhoen et al., 2008; Vogel et al., 2008). So far
few studies have described the effects of natural AhR ligands on DCs. We have
previously demonstrated that FICZ can generate phenotypical alterations in
BMDCs, similar to TCDD in BMDCs, demonstrating a lack of AhR ligand
specificity in DCs. These results raised the possibility that similar to TCDD, AhR
activation by FICZ could also induce the generation of regulatory DCs. FICZ
increased the expression of IDO1, IDO2, TGF-β2 and TGF-β3 and Aldh1a.
Although, we have not validated the activity of these suppressive mediators,
these results suggest that AhR-activation by FICZ could contribute to Treg
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development. However, further studies are needed to examine the effects of
FICZ-treated DCs on the polarization of T cells into Th17 or Tregs cells.

Several investigators have linked the generation of immune suppression
following TCDD exposure to the induction of Tregs (Marshall et al., 2008;
Quintana et al., 2008; Veldhoen et al., 2008). In a graft versus host model,
Marshall and colleagues demonstrated the suppressive function of TCDD-CD4+
T cells to be independent of Foxp3 expression, suggesting that ligand-activated
AhR functions as an alternative to Foxp3 in naïve T cells (Marshall et al., 2008).
Conversely, TCDD-induced suppression of EAE and diabetes in NOD mice has
been linked to increased Foxp3 expression (Kerkvliet, 2009). Despite these
studies, the mechanisms underlying the generation of AhR-induced Tregs remain
poorly understood.

Recent studies have suggested that DCs can induce Foxp3+ Tregs from
Foxp3- precursors in the presence of exogenous TGF-β (Sakaguchi et al., 2008).
TCDD-treated BMDCs showed increased expression of TGF-β3, IDO1 and IDO2,
raising the possibility that interactions of AhR-activated DCs with Foxp3- cells
could promote the generation of adaptive/inducible Tregs. Contrary to our
expectations, Foxp3+ cells were not induced by TCDD-treated BMDCs.
Additionally, TCDD-treated BMDCs stimulated with LPS failed to suppress
antigen-specific T cell activation in vivo. These results were surprising, as LPSmatured, TCDD-treated BMDCs displayed increased mRNA levels of IDO1, IDO2
and TGF-β3, indicative of a regulatory phenotype. Several possibilities could
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account for these observed effects. It is possible that TCDD does not increase
the function or activity of these mediators. In the absence of functionally active
DC-derived regulatory mediators, TCDD-treated BMDCs would not be expected
to induce Foxp3+ T cells. Several investigators have identified novel populations
of adaptive Tregs including CD4+CD25+Tregs, CD4+CD25-Foxp3- Tregs, IL-10induced Tregs, TGFβ-induced Tregs and CD8+CD28-Foxp3+ T cells (Weiner,
2001; Barrat et al., 2002; Zheng et al., 2002; Apostolou and von Boehmer, 2004;
Chen et al., 2004; Kretschmer et al., 2005; Battaglia et al., 2006; Roncarolo et
al., 2006; Hansen et al., 2007). The possibility that TCDD-treated BMDCs induce
the generation of one or more of these distinct Treg populations remains to be
tested. Studies described herein have exclusively assessed the effects of TCDDtreated DCs on the induction of adaptive Tregs. It remains to be tested whether
TCDD-treated DCs affect the maintenance or the expansion of natural Tregs.

In summary, we have demonstrated that although AhR activation induces
a regulatory phenotype in DCs, it does not contribute to induction of Treg. Our
results suggest that the generation of Tregs following AhR activation may not be
entirely attributable to DCs and that AhR activation of T cells may be essential for
the induction of regulatory T cells.
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CHAPTER 5
CONCLUSIONS

AhR activation by TCDD profoundly suppresses cell-mediated and
humoral immune responses. However, the specific mechanisms and molecular
targets underlying these immunotoxic effects remain undefined. Studies have
shown that expression of the AhR is inducible in lymphocytes and the debate
whether lymphocytes are direct or indirect targets of AhR activation continues. In
this context, it has been hypothesized that dendritic cells (DCs), that express
AhR constitutively, may be directly affected by TCDD and induce suppression of
T-cell mediated immune responses. To address this hypothesis Vorderstrasse
and colleagues, initially characterized the effects of AhR activation in DCs. Their
study demonstrated a decrease in splenic DCs concomitant with modulation of
maturation markers (Vorderstrasse and Kerkvliet, 2001). Although TCDD
decreased splenic DC numbers, no effect on the in vivo or in vitro antigen
processing ability of these DCs was observed. Later studies by Ruby et al.,
documented TCDD to suppress NF-kB/Rel activation (Ruby et al., 2002). Despite
these studies establishing DCs sensitivity to AhR activation, the consequences of
AhR activation on the innate and adaptive function of DCs remained undefined.
To address this deficiency, we investigated the consequences of AhR activation
on the fate and function of DCs. We postulated that AhR activation generates
defects in DCs, contributing to aberrant innate and adaptive immune responses,
culminating in TCDD-induced immune suppression.
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In our study we first examined the effects of AhR activation in steady-state
DCs in naïve mice. TCDD altered DC homeostasis by selectively decreasing the
CD11chighCD8α-33D1+ splenic DCs subset specialized at activating CD4+ T cells
but did not affect the regulatory CD11chighCD8α+DEC205+ splenic DCs. Thus,
decreases in the CD4+ T cell activating DCs by TCDD may significantly increase
susceptibility to infectious agents, especially pathogens that are considered
blood-borne. Corroborating these in vivo findings, recent data from our laboratory
has shown TCDD to decrease LPS- and CpG-induced IL-6 and TNF- α
production by Flt3L-derived, steady-state DCs in vitro (unpublished data).
Following pathogenic insult, TCDD-induced decreases in proinflammatory
cytokine production by DCs may lead to defective pathogenic clearance. Thus,
disruption of DC homeostasis as well as modulation of DC differentiation
following AhR activation would prevent DCs from effectively activating CD4+ T
cells, resulting in defective CD4+ T cell responses and immune suppression.

Recently, several reports have linked TCDD-induced immune suppression
with induction of Tregs (Funatake et al., 2005; Marshall et al., 2008). However,
little information exists on the mechanisms underlying induction of Tregs and
subsequent immune suppression following TCDD exposure. Dendritic cells
contribute to the generation of Tregs via multiple mechanisms. One such
mechanism is the production of Treg-inducing mediators such as IDO and TGFβ. Studies from our laboratory have shown an increased production of regulatory
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mediators including both IDO and TGF-β3 by steady-state DCs treated with
TCDD (unpublished data). Therefore, induction of Tregs and subsequent immune
suppression following TCDD exposure could result not only from a selective
retention of Treg-inducing CD11chighCD8α+DEC205+ DCs in the periphery, but
also from an increased production of suppressive mediators by steady-state
DCs. Taken together, in naive mice, AhR activation disrupts DC homeostasis,
inducing a loss of DCs that contribute to CD4+ T cell activation. The selective
loss of this subset, concomitant with the retention of Treg-inducing DCs may
increase susceptibility to infection and contribute to defective adaptive immune
responses following TCDD exposure.

Dendritic

cells

exist

in

multiple,

functionally

distinct

stages

of

differentiation both in vitro and in vivo. These include but are not limited to the
steady-state DCs and inflammatory DCs. As previously described, TCDD altered
steady-state DC homeostasis and differentiation. Inflammatory DCs, on the other
hand, constitute a novel DC population that are absent in the steady-state and
appear only following an inflammatory insult. Because we observed disruption of
steady-state DC homeostasis, we assessed the direct effects of AhR activation in
inflammatory DCs and the contribution of AhR-activated DCs in the generation of
inflammatory responses. TCDD induced a regulatory phenotype in inflammatory
DCs characterized by an increased expression of the suppressive mediators
IDO1, IDO2 and TGF-β3. The induction of a regulatory phenotype in
inflammatory DCs raised the possibility that interactions of these DCs with T cells
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may generate regulatory T cells or suppress T cell responses directly.
Surprisingly, despite the induction of regulatory mediators, AhR-activated DCs
did not suppress T cell activation, raising the possibility that AhR activation in
both T cells and DCs may be essential for Treg induction or suppression of T cell
activation. This possibility is consistent with studies from our laboratory
describing the effects of AhR activation in DCs during the generation of antigenspecific T cell responses. In our study, host mice treated with TCDD displayed
increased deletion of donor, antigen-laden DCs contributing to decreased
expansion of antigen-specific T cells. Though results from these experiments
demonstrated the requirement for the AhR in DCs to be essential for the
suppression of antigen-specific T cell responses, they did not exclude the
possibility that antigen-specific CD4+ T cells may be direct targets of AhR
activation resulting in suppression of T cell activation.

Recently, several non-DRE-mediated or non-canonical AhR signaling
mechanisms underlying toxic manifestations of TCDD have been identified. Of
these, interactions of activated AhR with NF-kB signaling components were
shown to induce defects in DCs following TCDD exposure (Ruby et al., 2002;
Vogel et al., 2008; Vogel and Matsumura, 2008). Consistent with these findings,
in our study, TCDD-induced modulation of inflammatory BMDCs and TLR
responsiveness was only partially dependent on DRE-mediated events and led to
altered NF-kB signaling. In addition to NF-kB signaling, an activated AhR
interacts with other transcription factors such as retinoblastoma and E2F1.
Assessing the potential interactions of the AhR with these transcription factors
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and others may provide further insight into mechanisms by which AhR activation
modulates DC function.

Traditionally referred to as an orphan receptor, recent studies have
identified candidate natural ligands for the AhR ranging from dietary components
such as flavones to bilirubin. In our study, natural AhR ligands, 6formylindolo[3,2-b]carbazole

(FICZ)

thiazolecarboxylic acid (ITE) altered

and

2-(1H-Indol-3-ylcarbonyl)-4-

DC differentiation suggesting that

endogenous or natural AhR ligands can also induce immunomodulation.
Additionally, recent studies have revealed physiological functions of the AhR. In
one of these studies, the AhR was shown to negatively regulate LPS-induced
inflammatory responses in macrophages, demonstrating that the physiologic
function of the receptor extends beyond mediating the toxicities of exogenous
environmental pollutants (Kimura et al., 2009). Characterizing the effects of
natural AhR ligands and their specific mechanisms in immune cells may provide
insights into the physiological functions of the AhR receptor in the immune
system and help devise strategies by which AhR activation can be therapeutically
exploited.

Taken together, our research describes the effects of AhR activation in
steady-state and inflammatory DCs and identifies mechanisms that may underlie
TCDD-induced immune suppression. Our results show that AhR activation
induces defects in DCs that could contribute to the generation of defective CD4+
T cell responses and subsequent immune suppression. In addition to DCs and
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CD4+ T cells, many different types of immune cells express the AhR. Future
studies examining the consequences of interactions between DCs and immune
cells such as the Natural Killer cells, B cells and CD8+T cells, in the context of
AhR activation, may unravel additional mechanisms underlying TCDD-induced
immune suppression and help understand the normal physiological function of
the AhR.

.
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